U.S. patent number RE41,408 [Application Number 11/799,608] was granted by the patent office on 2010-06-29 for method of providing sustained analgesia with buprenorpine. This patent grant is currently assigned to Purdue Pharma L.P.. Invention is credited to Paul D. Goldenheim, Robert F. Kaiko, Robert F. Reder.
United States Patent | RE41,408 |
Reder , et al. | June 29, 2010 |
**Please see images for: ( Certificate of Correction ) ** |
A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
Inventors: | Reder; Robert F. (Greenwich, CT), Kaiko; Robert F. (Weston, CT), Goldenheim; Paul D. (Wilson, CT) |
---|---|
Assignee: | Purdue Pharma L.P. (Stamford,
CT) |
Family ID: | 26715643 |
Appl. No.: | 11/799,608 |
Filed: | May 1, 2007 |
Application Number | Filing Date | Patent Number | Issue Date | ||
---|---|---|---|---|---|
11033107 | Jan 11, 2005 | ||||
08939068 | Sep 29, 1997 | 5968547 | |||
60038919 | Feb 24, 1997 | ||||
Reissue of: | 09311997 | May 14, 1999 | 06231886 | May 15, 2001 | |
Current U.S. Class: | 424/449; 424/443; 424/447; 424/446 |
Current CPC Class: | A61K 9/7053 (20130101); A61P 25/04 (20180101); A61K 9/7023 (20130101); A61P 29/00 (20180101); A61P 25/00 (20180101); A61K 9/0014 (20130101); A61K 31/485 (20130101); A61K 31/4748 (20130101); A61P 25/36 (20180101); A61K 9/0019 (20130101); A61K 9/7061 (20130101) |
Current International Class: | A61F 13/00 (20060101); A61K 9/70 (20060101) |
Field of Search: | ;424/449,443,446,447,489 |
3996934 | December 1976 | Zaffaroni |
4058599 | November 1977 | Bauer et al. |
4060084 | November 1977 | Chandrasekaran et al. |
4119713 | October 1978 | Carosio |
4262003 | April 1981 | Urquhart et al. |
4379454 | April 1983 | Campbell et al. |
4582835 | April 1986 | Lewis et al. |
4588580 | May 1986 | Gale et al. |
4673679 | June 1987 | Aungst et al. |
4784855 | November 1988 | Yamashita et al. |
4806341 | February 1989 | Chien et al. |
4879297 | November 1989 | Mahjour et al. |
4906463 | March 1990 | Cleary et al. |
4908027 | March 1990 | Enscore et al. |
4938759 | July 1990 | Enscore et al. |
4945103 | July 1990 | Cohen |
4956171 | September 1990 | Chang |
4983395 | January 1991 | Chang et al. |
4994278 | February 1991 | Sablotsky et al. |
5026556 | June 1991 | Drust et al. |
5028435 | July 1991 | Katz et al. |
5069909 | December 1991 | Sharma et al. |
5075341 | December 1991 | Mendelson et al. |
5090405 | February 1992 | Jansen et al. |
5091186 | February 1992 | Miranda et al. |
5132115 | July 1992 | Wolter |
5149538 | September 1992 | Granger et al. |
5176916 | January 1993 | Yamanaka et al. |
5225199 | July 1993 | Hidaka et al. |
5225440 | July 1993 | London et al. |
5236714 | August 1993 | Lee et al. |
5238933 | August 1993 | Catz et al. |
5240711 | August 1993 | Hille et al. |
5272149 | December 1993 | Stalling |
5306503 | April 1994 | Muller et al. |
5336210 | August 1994 | Hidaka et al. |
5342623 | August 1994 | Enscore et al. |
5344656 | September 1994 | Enscore et al. |
5352457 | October 1994 | Jenkins |
5462745 | October 1995 | Enscore et al. |
5486362 | January 1996 | Kitchell et al. |
5580876 | December 1996 | Crain et al. |
5613958 | March 1997 | Kochinke et al. |
5635203 | June 1997 | Gale et al. |
5683711 | November 1997 | Fischer et al. |
5700480 | December 1997 | Hille et al. |
5732717 | March 1998 | Watanabe et al. |
5785991 | July 1998 | Burkoth et al. |
5814032 | September 1998 | Hori et al. |
5817665 | October 1998 | Dante et al. |
5830505 | November 1998 | Fischer et al. |
5834010 | November 1998 | Quan et al. |
5837289 | November 1998 | Grasela et al. |
5843468 | December 1998 | Burkoth et al. |
5900420 | May 1999 | Cole |
5919473 | July 1999 | Elkhoury |
5942530 | August 1999 | Panetta |
5968547 | October 1999 | Reder et al. |
5989585 | November 1999 | Bracher |
6004969 | December 1999 | Hu |
6024974 | February 2000 | Li |
6024976 | February 2000 | Miranda et al. |
6096756 | August 2000 | Crain et al. |
6165499 | December 2000 | Kleinsorgen et al. |
6210699 | April 2001 | Acharya et al. |
6231886 | May 2001 | Reder et al. |
6242456 | June 2001 | Shuster et al. |
6264980 | July 2001 | Hille |
6280766 | August 2001 | Becher et al. |
6344212 | February 2002 | Reder et al. |
6391294 | May 2002 | Dettmar et al. |
6436977 | August 2002 | Thompson |
6554851 | April 2003 | Palasis et al. |
6595956 | July 2003 | Gross et al. |
6787149 | September 2004 | El Khoury et al. |
6865444 | March 2005 | Howard |
7011843 | March 2006 | Becher et al. |
7056527 | June 2006 | Maruo et al. |
7270830 | September 2007 | Reidenberg |
2001/0051186 | December 2001 | Acharya et al. |
2002/0137761 | September 2002 | Crain et al. |
2003/0104976 | June 2003 | Davar et al. |
2003/0114475 | June 2003 | Fox et al. |
2004/0146547 | July 2004 | Marcenyac et al. |
2004/0241218 | December 2004 | Tavares |
3526339 | Jan 1992 | DE | |||
3546830 | Jul 1995 | DE | |||
19840758 | Mar 2000 | DE | |||
0368409 | May 1990 | EP | |||
430019 | Jun 1991 | EP | |||
432945 | Jun 1991 | EP | |||
819438 | Jan 1998 | EP | |||
821957 | Feb 1998 | EP | |||
1422230 | May 2004 | EP | |||
2165148 | May 1989 | GB | |||
166095 | Mar 1995 | PL | |||
9619975 | Dec 1994 | WO | |||
95/01167 | Jan 1995 | WO | |||
95/20393 | Aug 1995 | WO | |||
96/19975 | Jul 1996 | WO | |||
1997-004835 | Feb 1997 | WO | |||
97/48380 | Dec 1997 | WO | |||
1998-026780 | Jun 1998 | WO | |||
98/36728 | Aug 1998 | WO | |||
1999-012529 | Mar 1999 | WO | |||
1999-032120 | Jul 1999 | WO | |||
2000-035456 | Jun 2000 | WO | |||
2002-070524 | Sep 2002 | WO | |||
2002-085268 | Oct 2002 | WO | |||
2003-079945 | Oct 2003 | WO | |||
2004-103317 | Dec 2004 | WO | |||
2005-011579 | Feb 2005 | WO | |||
72 Buprenorphine, MNH/PAD/87.11, pp. 29-63 (1987). cited by other . BTDS List of Studies (Mar. 30, 2000). cited by other . Buprenorphine prescription withdrawn in Norway, available at http://www.drugscope.org.uk (Sep. 21, 2001). cited by other . Buprenorphine TDS Pre-NDA Meeting. Flux rate analysis of Buprenorphine transdermal delivery systems (BTDS) (Jun. 9, 1999). cited by other . Lasseter et al., Systemic pharmacokinetic (PK) study of buprenorphine (B) in mild to moderate chronic hepatic impairment (CHI). Amer Soc for Clin Phamcol and Therapeut. PI-4. (Feb. 2001). cited by other . Rigas et al., "Transdermal fentanyl: Practical use in the hospital and the home" ASHP Midyear Clinical Meeting v. 27 (1992). cited by other . The Safety of High Doses of Buprenorphine. Tables of Contents and Introduction (Feb. 22, 2002). cited by other . Cymbalta.RTM. ((duloxetine hydrochloride) Delayed-release Capsules) Physician's Desk Reference 59.sup.th ed., 2005. cited by other . Opana.RTM. ER ((Oxymorphone Hydrochloride) Extended Release Tablets) Physician's Desk Reference 61.sup.st ed., 2007. cited by other . Cranmer K., Laudau CJ, Friedman My Turner NG, Ripa SR. The Safety and tolerability 0 of 7-day buprenorphine TDS in the analgesic management of pain in the elderly--a six-month evaluation. www.ASCP.com/education/postersandpapersam05.com. Poster 34. (Study BUP3002S) (Nov. 2005). cited by other . Definition of "Aldehyde," printed on Sep. 1, 2009 from Answers.com. cited by other . Definition of "Photoinitiator," printed on Sep. 1, 2009 from Answers.com. cited by other . Definition of "Polymerize," printed on Sep. 1, 2009 from Answers.com. cited by other . Definition of "Tannin," printed on Sep. 1, 2009 from Wikipedia.org, the free cncyclopedia.. cited by other . Bauer, KH (ed.) Pharmaceutische Technologie pp. 362-365 (1993). cited by other . Budd, K., Experience with partial agonists in the treatment of cancer pain in: Doyle, D (ed.), Opioids in the Treatment of Cancer Pain, Royal Society of Medicine Services International Congress and Symposium Series No. 146 (1990). cited by other . Burke et al., "Increased rates of drug abuse and dependence after onset of mood or anxiety disorders in adolescence" Hospital & Community Psychiatry 45(5): 451-455 (1994) (Abstract only). cited by other . Curran et al., "Recognition and management of depression in a substance use disorder treatment population" American Journal of Drug & Alcohol Abuse 33(4): 563-569 (2007) (Abstract only). cited by other . Currie et al., "Comorbidity of major depression with substance use disorders" Canadian Journal of Psychiatry 50(10): 660-666 (2005). cited by other . Davis et al., "Major despression and comorbid substance use disorders" Current Opinions in Psychiatry 21(1): 14-18 (2008). cited by other . Declaration of Prof. Jonathan Hadgraft dated Apr. 22, 2009. cited by other . Declaration of Prof. Jonathan Hadgraft dated Jul. 9, 2004. cited by other . Declaration of Prof. Jonathan Hadgraft dated Oct. 8, 2004. cited by other . Declaration of Prof. Jonathan Hadgraft dated Oct. 11, 2007. cited by other . Driscoll, CE Primary Care14(2): 337-352 (1987). cited by other . Excerpt of Review for Approval issued Aug. 7, 1990 by the FDA for Duragesic.RTM.. cited by other . Grond, S et al. Pain 69: 191-198 (1997). cited by other . Heilman, N Therapcutische Systeme, 4.sup.th ed., Stuttgart: Enke pp. 67-77 and 83-86 (1984). cited by other . Heilman, N Therapcutische Systeme, 4.sup.th ed., Stuttgart: Enke pp. 104-106 (1984). cited by other . Introduction to the Pharmacology of Opioids (Apr. 23, 2009). cited by other . Jin-Jie, G. "Synthesis of biodegradable polyurethane foams from condensed tannin and bark of Acacia mearnsii" Bull. Kyushu Univ. For. 79: 21-85 (1998). cited by other . Landau, CJ et al., "Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study" Clinical Therapeutics 29(10): 2179-2193 (2007). cited by other . Markou et al., "Neurobiological similarities in depression and drug dependence: a self-medication hypothesis" Neuropsychopharmagology 18(3): 135-174 (1998). cited by other . Mongan, Mary Louise Hack The Effects of Low Dose Buprenorphine on Selected Psychiatric Patients San Francisco State University, San Francisco, CA. 1992, 105 ppg. cited by other . Nagle, CJ et al., Current Anaesthesia and Care 1: 247-252 (1990). cited by other . Office Actions dated Sep. 19, 2008 and Feb. 9, 2009, issued in the prosecution of U.S. Appl. No. 10/394,425 to Kaiko et al., filed Mar. 20, 2003. cited by other . Office Actions dated Dec. 15, 2008, Feb. 18, 2009 and Apr. 6, 2009, issued in the prosecution of U.S. Appl. No. 10/476,601 to Tavares et al., filed Nov. 20, 2003. cited by other . Physician's Desk Reference 49.sup.th ed., 1995, entry on Duragesic.RTM.. cited by other . Physician's Desk Reference 50.sup.th ed., 1996, entry on Duragesic.RTM.. cited by other . Product Monograph for Duragesic.RTM. (2008). cited by other . Regier et al., "Comorbility of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) Study" JAMA 264(19): 2549-2550 (990) (Abstract only). cited by other . Roy, SD et al., J. Pharmaceutical Sciences 83: 1723-1728 (1994). cited by other . Sorrell, DC Nursing 24:30 (1994). cited by other . Southam, MA Anti-Cancer Drugs 6(suppl. 3): 29-34 (1995). cited by other . Steiner, D et al., "The efficacy and safety of buprenorphine transdermal system (BTDS) in subjects with moderate to severe low back pain" Presentation #305, PowerPoint Presentation at American Pain Society Annual Meeting, May 6-9, 2009, San Diego, CA. cited by other . Subramaniam et al., "Baseline depressive symptoms predict poor substance use outcome following adolescent residential treatment" Journal of the American Academy of Child & Adolescent Psychiatry 46(8): 1062-1069 (2007) (Abstract only). cited by other . Swendsen et al., "The comorbidity of depression and substance use disorders" Clin. Psychol. Rev. 20(2): 173-189 (2000) (Abstract only). cited by other . Wall, PD, et al., Textbook of Pain 2.sup.nd ed., New York: Churchill Livingstone, pp. 686-701 (1989). cited by other . Woodroffe, MA et al., Canadian Family Physician 43: 268-272 (1997). cited by other . Hexal AG Opposition against EP-B-964677, dated May 15, 2007. (in German, w/ Engl. translation). cited by other . Novosis AG Opposition against EP-B-964677, dated May 15, 2007. (in German, w/ Engl. translation). cited by other . Letter from counsel for Purdue Pharma LP, dated Dec. 20, 2007, to EPO re EP-B-964677 opposition proceedings (English). cited by other . Summons to attend oral proceedings pursuant to Rule 115(1) EPC re EP-B-964677 opposition proceedings dated Dec. 29, 2008. cited by other . Letter from counsel for Acino AG (previously Novosis AG), dated Apr. 17, 2009, to EPO re EP-B-964677 opposition proceedings. (in German, w/ Engl. translation). cited by other . Letter from counsel for Purdue Pharma LP, dated Apr. 23, 2009, to EPO re EP-B-964677 opposition proceedings (English). cited by other . Letter from counsel for Purdue Pharma LP, dated Jun. 4, 2009, to EPO re EP-B-964677 opposition proceedings (English). cited by other . Minutes of the oral proceedings before the Opposition Division held Jun. 23, 2009 re: EP-B-964677. cited by other . Decision revoking the European Patent EP-B-964677, dated Jul. 24, 2009. cited by other . Japanes Supreme Court, Third Petty Branch decision dated Jan. 16, 2007. (English translation). cited by other . Abse et al., "The poppy: therapeutic potential in cases of dementia with depression" Ann. NY Acad. Sci. 398: 79-83 (1982). cited by examiner . Ahmedzai, S, "New approached to pain control in patients with cancer" Eur. J. Cancer 33(Suppl. 6): S8-S14 (1997). cited by examiner . Akatsuka et al., "The relief of postoperative pain by suppositories of buprenorphine or NSAID" Masui 45(3): 298-303 (1996). (Abstract). cited by examiner . Al-Gommer O. Sexual dysfunctions in male opiate users: A comparative study of heroin, methadone, and buprenophine. Addictive Disorders and their Treatment 2007; 6(3):137-43. cited by examiner . Ang-Lee K. Single dose of 24 milligrams of buprenorphine for heroin detoxification: An open-label study of five inpatients. Journal of psychoactive drugs 2007; 38(4):505-12. cited by examiner . Bates' Guide to Physical Examination and History Taking, 6th ed., Bickley t al., eds., Lippincott Williams & Wilkins Publishers, 1995, pp. 276-280. cited by examiner . Bellamy N, Buchanan W W, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important subject relevant outcomes to antirheumatic drug therapy in subjects with osteoarthritis of the hip or knee. J Rheumatol 1988; 15:1833-1840. cited by examiner . Bellamy N, Campbell J, Hill J, Band P. A comparative study of telephone versus onsite completion of the WOMAC: 3.0 Osteoarthritis Index. J Rheumatol 2002; 29:783-786. cited by examiner . Bellamy N. WOMAC Osteoarthritis Index. a user's guide. London, Ontario, Canada: Victoria Hospital Corporation, 1995. cited by examiner . Bentley et al., "Age and fentanyl pharmacokinetics" Anesth. Analg. 61: 968-971 (1982). cited by examiner . Berrocoso et al., "Differential role of 5-HT1A and 5-HT1B receptors on the antinociceptive and antidepressant effect of tramadol in mice" Psychopharmacology 188(1): 111-118 (2006). cited by examiner . Bodkin et al., "Buprenorphine treatment of refractory depression" J. Clin. Psychopharmacology, 15(1): 49-57 (1995). cited by examiner . Bonica, JJ, "Past and current status of pain research and therapy" Semin. Anesth. 5:82-99 (1986). cited by examiner . Brema et al., "Oral tramadol and buprenorphine in tumor pain. An Italian multicentre trial" Int. J. Clin. Pharm. Rex. 16(4/5): 109-116 (1996). cited by examiner . Brenn et al., "Epidural analgesia in children with cerebral palsy" 45(12): 1156-1161 (1998). cited by examiner . Buchwald et al., "Quantitative structure-metabolism relationships: Steric and non-steric effects in the enzymatic hydrolysis of noncongener carboxylic esters" J. Med. Chem. 42:5160-5168 (1999). cited by examiner . Bundgaard, H (ed.) Design of Prodrugs Elsevier: Amsterdam, New York 1985. cited by other . Callaway, E., "Buprenorphine for depression: The un-adoptable orphan" Biol. Psychiatry 39: 989-990 (1996). cited by other . Callesen et al., "Prospective study of chronic pain after groin hernia repair" Br. J. Surg. 86: 1528-1531 (1999). cited by other . Capogna et al., "Intrathecal buprenorphine for postoperative analgesia in the elderly patient" Anaesthesia 43: 128-130 (1988). cited by other . Cathelin et al., "Comparison between the side-effects of buprenorphine and morphine in conscious man" Anesth. Analg. (Paris) 37(5-6): 283-293 (1980). English abstract. (Original in French). cited by other . Cherny, J., "New strategies in opioid therapy for cancer pain" J. Oncol. Management 9: 8-15 (2000). cited by other . Cirado et al., "Reduction of isoflurane MAC with buprenorphine and morphine in rats" Laboratory Animals 34(3): 252-9 (2000). cited by other . Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med 1994;23(2):129-138. cited by other . Coli et al., "Evaluation of the effectiveness of NSAIDs in the prevention of postoperative pain. Comparison between pre-and postoperative administration of sodium naproxen in orthopedic surgery" Minerva Anestesiol. 59(10): 531-535 (1993). (Abstract). cited by other . Crook et al., "The prevalence of pain complaint in a general population" Pain 18: 299-314 (1984). cited by other . Daut RL, Cleeland,CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17:197-210. cited by other . Davids et al., "Buprenorphine in the treatment of opioid dependence" European Neuropsychopharmacology 14: 209-216 (2004). cited by other . Dayer et al., "Pharmacology of tramadol" Drugs 53(Suppl. 2): 18-24 (1997). English abstract. (Original in French). cited by other . Dean et al., "Depressive symptoms during buprenorphine vs. methadone maintenance: Findings from a randomized, controlled trial in opioid dependence" European Psychiatry 19: 510-513 (2004). cited by other . Desjardins et al., "The injectable cyclooxegenase-2 specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively" Anesth. Analg. 93: 721-727 (2001). cited by other . Dionne et al., "Evaluation of preoperative ibuprofen for postoperative pain after removal of third molars" Oral Surgery 45: 851-856 (1978). cited by other . Dionne et al., "Suppression of postoperative pain by preoperative administration of ibuprofen in comparison to placebo, acetaminophen, and acetaminophen plus codeine" J. Clin. Pharmacol. 23: 37-43 (1983). cited by other . Dum et al., "Opioids and Motivation" Interdisciplinary Science Reviews 12(2): 180-190 (1987). cited by other . Eder et al., "Buprenorphine in der Schwangerschaft" Psychiat. Prax. 28: 267-269 (2001). (XP009068360). (Abstract). cited by other . Eke et al., "An open comparative study of dispersible piroxicam versus soluble acetylsalicylic acid for the treatment of osteoarticular painful attack during sickle cell crisis" Tropical Medicine and International Health 5(2): 81-84 (2000). cited by other . Emrich et al. "Antidepressant effects of buprenorphine" Lancet 2: 709 (1982). cited by other . Emrich et al., "Current perspectives in the pharmacopsychiatry of depression and mania" Neuropharmacology 22(3 Special No.): 385-388 (1983). cited by other . Emrich et al., "Possible antidepressive effects of opioids: action of buprenorphine" Ann. NY Acad. Sci. 398: 108-112 (1982). cited by other . Emrich, HM, in: "Typical and Atypical Antidepressant: Clinical Practice" Costa et al., (Eds.), Raven Press: New York, 1982 pp. 77 et seq. cited by other . Holloway, M. (Erickson, D.), "Rx for addiction" Sci. Am. 264(3): 94-103 (1991). cited by other . Etchepare F, Coutaux A, Edel Y, Bourgeois P. Enterobacter cloacae spondylodiscitis through misuse of high-dose intravenous buprenorphine. La Presse Medicale 2005; 34(10):729-731. cited by other . Everhart et al., "Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine" Clin. Chem. 43(12): 2292-2302 (1997). cited by other . Extein et al., "Deficient prolactin response to morphine in depressed patients" Am. J. Psychiatry 137: 845-846 (1980). cited by other . Extein et al., "Methadone and morphine in depression" Psychopharmacol. Bull. 17(1): 29-33 (1981). cited by other . Faponle, AF, "Management of pain after surgery--A Short Review " Nigerian Journal of Medicine 10(3): 112-115 (Jul./Sep. 2001). cited by other . Feinberg et al., "The effect of morphine on symptoms of endogenous depression" in: Harris,(ed.) Problems of Drug Dependence, 1982 National Institute on Drug Abuse Research Monograph 43 pp. 245-250 (1982). cited by other . Ferrell et al., "Principles of pain management in older people" Compr. Ther. 17: 53-58 (1991). cited by other . Ferrell, BA, "Pain avaluation and management in the nursing home" Ann. Int. Med.123(9): 681-687 91995). cited by other . Fischer et al., "Treatment of opioid-dependent pregnant women with buprenorphine" Addiction 95(2): 239-244 (2000). (Abstract). cited by other . Fletcher D, "Prevention of postoperative pain" Ann. Fr. Anesth. Reanim. 17(6): 622-632 (1998). (Abstract). cited by other . Gautschi OP, Zellweger R. Images in emergency medicine. Extensive groin abscess and myositis after intravenous cubital buprenorphine injection. Annals of Emergency Medicine 2006; 48(6): 656-659. cited by other . Gerra et al., "Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study" Progress in Neuro-Psychopharmacology & Biological Psychiatry 30: 265-272 (2006). cited by other . Gerra et al., "Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome" Drug and Alcohol Dependence 75: 37-45 (2004). cited by other . Glasper et al., "Induction of patients with moderately severe methadone dependence onto buprenorphine" Addiction Biology 10: 149-155 (Jun. 2005). cited by other . Gold et al., "Antimanic, antidepressant, and antipanic effects of opiates: clinical, neuroanatomical, and biochemical evidence" Ann. NY Acad. Sci. 398: 140-150 (1982). cited by other . Gold et al., "Clinical evidence of antidepressant and antipanic effects of opiates" Am. J. Psychiatry 136: 982-983 (1979). cited by other . Goldstein, "Methadone for depression" Biol. Psychiatry 19: 1272-1273 (1984). cited by other . Golianu, B., "Pediatric acute pain management" Pediatr. Clin. North Am. 47(3): 559-587 (2000). cited by other . Goodman & Gilman's The Pharmacological Basis of Therapeutics Hardman, JG (ed.) McGraw-Hill Professional Publishing, 2001, p. 586. cited by other . Goodman & Gilman's The Pharmacological Basis of Therapeutics Hardman, JG (ed.) McGraw-Hill Professional Publishing, 2001, pp. 31-32. cited by other . Goodman & Gilman's The Pharmacological Basis of Therapeutics Hardman, JG (ed.) Mc-Graw-Hill Professional Publishing, 2001, pp. 530-532. cited by other . Griffin et al., "High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease" N. Engl. J. Med. 330(11): 733-737 (1994). cited by other . Guideline for Industry--Clinical Safety Data management: Definitions and Standards for Expedited Reporting ICH-E2A, Mar. 1995, pp. 5-7. cited by other . Hambrook JM, Rance MJ. The interaction of buprenorphine with opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz HW, editor. Opiates and endogenous opioid peptides. Amsterdam: Elsevier/North Holland, Biomedical Press; 1976. p. 295-301. cited by other . Hannibal et al., "Preoperative wound infiltration with bupivacaine reduces early and late opioid requirement after hysterectomy" Anesth. Analg. 83: 376-381 (1996). cited by other . Heel et al., Curr. Ther. 5: 29-33 (1979). cited by other . Hoffman D, Friedman M, Colucci S, Richards, P, Zhang P. Validation of the Brief Pain Inventory for subjects with osteoarthritis. J Pain 2002; 3(2):(Suppl)3. cited by other . Huang et al., "Atmospheric pressure ionization mass spectrometry" Anal. Chem. 62(13): 713A-725A (1990). cited by other . Inagaki et al., "Mode and site of analgesic action of epidural buprenorphine in humans" Anesth. Analg. 830: 530-536 (1996). cited by other . International Search Report, PCT/US2003/039793, dated Mar. 31, 2004, 2ppgs. cited by other . Jacobsen et al., "Age-related changes in sebaceous wax ester secretion rates in men and women" J. Invest. Dermatol. 85: 483-485 (1985). cited by other . Jakobovits SL, Mcdonough M, Chen RY. Buprenorphine-associated gastroparesis during in-patient heroin detoxification. Addiction 2007, 101:490-491. cited by other . Jernite et al., "Buprenorphine and pregnancy. Analysis of 24 cases" Arch. Pediatr. 6:1179-1185 (1999). cited by other . Juhlin-Dannfelt et al., "Premedication with sublingual buprenorphine for out-patient arthroscopy: Reduced need for postoperative pethidine but higher incidence of nausea" Acta Anaesthesio. Scand. 39: 633-636 (1995). cited by other . Kaliha H. A prospective study on buprenorphine use during pregnancy: Effects on maternal and neonatal outcome. Acta Obstetricia et Gynecologica Scandinavica 2007; 86(2): 185-90. cited by other . Kaliha H. Brain magnetic resonance imaging of infants exposed prenatally to buprenorphine. Acta Radiologica 2007; 48(2): 228-31. cited by other . Kakinohana et al., "Pre-emptive analgesia with intravenous ketamine reduces postoperative pain in young patients after appendectomy: A randomized control study" Masui 49(10): 1092-1096 (2000). (Abstract). cited by other . Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons (2nd edition). 2002, pp. 22-23. cited by other . Kenny et al., Clin. Geriatr. 8: 1-4 (2000). cited by other . Kinney et al., AACN's Clinical Reference Clinical Reference for Critical Care Nursing, Mosby, 4th ed., 1998, pp. 285-287. cited by other . Kokki et al., "Comparison of pre-and postoperative administration of ketoprofen for analgesia after tonsillectomy in children" Pediatric Anesthesia 12(2): 162-167 (2002). cited by other . Kosten et al., "Depressive symptoms during buprenorphine treatment of opioid abusers" Journal of Substance Abuse Treatment 7: 51-54 (1990). cited by other . Lehmann et al., "Treatment of depression with dexedrine and demerol" Curr. Therapeutic Res. Clin. Exp. 13(1): 42-49 (1971). cited by other . Lichtenstein et al., "Disaggregating pain and its effect on physical functional limitations" J. Gerontol 53(5): M361-M371 (1998). cited by other . Lintzeris N. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. Journal of clinical psychopharmacology 2006; 26(3):274-283. cited by other . Lovell et al., "Type I and III collagen content and fibre distribution in normal human skin during ageing" Br. J. Dermatol. 117: 419-328 (1987). cited by other . Luukinen et al., "Prognosis of diastolic and systolic orthostatic hypotension in older persons" Arch. Int. Med. 159: 273-280 (1999). cited by other . Marek, GJ "Behavioral evidence for .mu.-opioid and 5-HT2A receptor interactions" European Journal of Pharmacology 474: 77-83 (2003). cited by other . Markowitz et al., "Venlafaxine-tramadol similarities" Med. Hypotheses 51(2): 167-168 (1998). cited by other . Maruyama S, Nomura Y, Fukushige T, Eguchi T, Nishi J, Yoshinaga M, Kawano Y. Suspected Takotsubo cardiomyopathy caused by withdrawal of buprenorphine in a child. Circulation Journal 2006; 70:509-511. cited by examiner . Matussek et al., "Investigations with the specific .mu.-opiate receptor antagonist fentanyl in depressive patients: Growth hormone, prolactin, cortisol, noradrenaline and euphoric responses" Neuropsychobiology 21: 1-8 (1989). cited by examiner . McCance-Katz EF. Interaction between buprenorphine and atazanavir/ritonavir. Drug and Alcohol Dependence 2007; 91(2-3):269-78. cited by examiner . Mello et al., "Buprenorphine treatment of opirate and cocaine abuse: Clinical and Preclinical studies" Harvard Rev. Psychiatry 1: 168-183 (1993). cited by examiner . Melon et al., "Buprenorphine. Haemodynamic study" Anesth. Analg. (Paris) 37(3-4): 121-125 (1980). English abstract. (Original in French.). cited by examiner . Mendelson et al., "Dose proportionality of 4, 8, 16 and 32 mg sublingual buprenorphine solutions" American Society for Clinical Pharmacology and Therapeutics 65(2): 154 Abstract P11-28 (1999). cited by examiner . Mercadante et al., "Alternatives to oral opioids for cancer pain" Oncology 13(2): 215-220 (1999). cited by examiner . Mercadante, "Opioid rotation in cancer pain: rationale and clinical aspects" Cancer 86:1 1856-66 (1999). cited by examiner . Mobily et al., "An epidemiologic analysis of pain in the elderly" J. Aging Health 6: 139-154 (1994). cited by examiner . Mongan et al., "Buprenorphine responders" Biol. Psychiatry 28: 1078-1080 (1990). cited by examiner . Moragas et al., "Image analysis of dermal collagen changes during skin aging" Analyt. Quant. Cytol. Histol. 20: 493-499 (1998). cited by examiner . Nanovskaya et al., "Transplacental transfer and metabolism of buprenorphine" J. Pharmacol. Exp. Ther. 300(1): 26-33 (2002). cited by examiner . Noble et al., "Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs" Expert Opinion on Therapeutic Targets 11(2): 145-159 (Nov. 2007). cited by examiner . Nolan et al., "Anaesthesia and pain management in cerebral palsy" Anaesthesia 55:(1): 32-41 (2000). cited by examiner . Nyhuis et al., "Opiate receptors in ECT--resistant depression" European Neuropsychopharmacology 15(3): S420 (2005). cited by examiner . Oda et al., "Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro" Br. J. Anaesthesia 82(6): 900-903 (1999). cited by examiner . Oliveto et al., "Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users" Journal of Substance Abuse Treatment 12(6): 423-428 (1995). cited by examiner . Paetzold et al., "Buprenorphine: therapeutical use in opioid-dependence, depression and schizophrenia" Nervenheilkunde 19(3): 143-150 (2000). (w/ English abstract). cited by examiner . Pani et al., "Buprenorphine: A controlled clinical trial in the treatment of opioid dependence" Drug and Alcohol Dependence 60: 39-50 (2000). cited by examiner . Parmelee et al., "Assessment of pain in the elderly" Annual Review of Gerontology and Geriatrics 14: 281-301 (1994). cited by examiner . Pereira et al., "Analgesic effects of diclofenac suppository and injection after postoperative administration" Int. J. Clin. Pharm. Res. 19(2): 47-51 (1999). cited by examiner . Perttunen et al., "Chronic pain after thoracic surgery: a follow-up study" Acta Anaesthesiol. Scand. 43: 563-567 (1999). cited by examiner . Pickar et al., "Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients" Am. J. Psychiatry 138: 160-166 (1981). cited by examiner . Potter, Fundamentals of Nursing, Mosby, 4th ed., 1997, p. 633. cited by examiner . Reddy L, Kranjnik M, Zylicz Z. Transdermal buprenorphine may be effective in the treatment of pruritus in primary biliary cirrhosis. Journal of Pain and Symptom Management 2007; 34(5):455-456. cited by examiner . Romero et al., "Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective .mu./.kappa.antagonist in the [.sup.35S]-GTP-.gamma.-S functional binding assay" Synapse 34: 83-94 (1999). cited by examiner . Rooke et al., "Maximal skin blood flow is decreased in elderly men " J. Appl. Physiol. 77: 11-14 (1994). cited by examiner . Rothman et al., "An open-label study of a functional opiod .kappa. antagonist in the treatment of opioid dependence" Journal of Substance Abuse Treatment 18: 277-281 (2000). cited by examiner . Russo and Brose, Ann. Rev. Med. 49: 123-133 (1998). cited by examiner . Schriek P. Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases. European Support Care Cancer 2004; 12:882-884. cited by examiner . Seet RCS, Lim ECH. Intravenous use of buprenorphine tablets associated with rhabdomyolysis and compressive sciatic neuropathy. Annals of Emergency Medicine 2006; 47(4):396-397. cited by examiner . Seet RCS, Rathakrishnan R, Chan BP, Lim ECH. Diffuse cystic leucoenphalopathy after buprenorphine injection. Journal of Neurology, Neurosurgery and Psychiatry 2005; 76(6):890-891. cited by examiner . Seidenari et al., "Echographic evaluation with image analysis of normal skin: variation according to age and sex" Skin Pharmacol. 7:201-209 (1994). cited by examiner . Seifert et al., "Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone" Pharmacopsychiatry 35: 159-164 (2000). cited by examiner . Seifert et al., "Mood and affect during detoxification of opiate addicts: A comparison of buprenorphine versus. methadone" Addiction Biology 10: 157-164 (Jun. 2005). cited by examiner . Shapira et al., "Treatment of refractory major depression with tramadol monotherapy" Am. J. Psychiatry 62(3): 205-206 (2001). cited by examiner . Ssheikh et al., "Geriatric Depression Scale: Recent evidence and development of a shorter version" Clin. Gerontol. 5: 165-173 (1986). cited by examiner . Singh J, Grover S, Basu D. Very high-dose intravenous buprenorphine dependence: A case report. German J Psychiatry 2004; 7:58-59. cited by other . Soyka M, Penning R, Wittchen U. Fatal poisoning in methadone and buprenorphine treated patients--are there differences? Pharmacopsychiatry 2006; 39:85-87. cited by other . Spyker et al., Clin. Pharmacol. Ther. 67(2): 145, Abstract P11-12. cited by other . Stanway, GW, "A preliminary investigation comparing pre-operative morphine and buprenorphine for postoperative analgesia and sedation in cats" Veterinary Anaesthesia and Analgesia 29: 29-35 (2002). cited by other . Stewart et al., eds., "Medical Outcomes Study Pain Evaluation" in: Measuring Functioning and Well-Being--The Medical Outcomes Study Approach, Durham and London: Duke University Press, 1992. cited by other . Stinchcomb et al., "A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters" Pharmaceutical Research 12(10): 1526-1529 (1995). cited by other . Supplementary partial European Search Report for EP Application No. 03721427, dated Mar. 31, 2006. cited by other . Tanaka et al., "Preoperative fluribiprofen provides pain relief after laparascopic cholecystectomy" Masui 46(5): 679-683 (1997). Abstract). cited by other . Tauzin-Fin et al., "Effect of balanced analgesia with buprenorphine on pain response and general anesthesia requirement during lithotripsy procedures" European Journal of Anaesthesiology 15: 147-152 (1998). cited by other . Thompson et al., "Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients" Br. J. Anaesth. 81: 152-154 (1998). cited by other . Torrens et al., "Buprenorphine versus heroin dependence: Comparison of toxicologic and psychopathologic characteristics" Am. J. Psychiatry 150(5): 822-824 (1993). cited by other . Varga et al., "The effect of codeine on involutional and senile depression" Ann. NY Acad. Sci. 398: 103-105 (1982). cited by other . Verhaeverbeke et al., "Drug-induced orthostatic hypotension in the elderly: avoiding its onset" Drug Safety 17: 108-118 (1997). cited by other . Vibbert et al., eds., "Modified Brief Pain Inventory," in: The 1995 Medical Outcomes and Guidelines Sourcebook,New York: Faulkner & Gray, Inc., 1994, pp. 269-270. cited by other . Walsh et al., "Acute administration of buprenorphine in humans: Partial agonist and blockade effects" The Journal of Pharmacology and Experimental Therapeutics 274(1): 361-372 (1995). cited by other . Weber et al., "Current and historic concepts of opiate treatment in psychiatric disorders" Int. Clin. Psychopharmacology 3: 255-266 (1988). cited by other . Weiss et al., "Analysis of the diminished skin perfusion in elderly people by laser doppler flowmetry" Age Ageing 21: 237-241 (1992). cited by other . Williams et al., "Case-finding for depression in primary care: a randomized trial" Am. J. Med. 106(1): 36-43 (1999). cited by other . Woods et al., "Efficacy of nalbuphine as a parenteral analgesic for the treatment of painful episodes in children with sickle cell disease" J. Assoc. Acad. Minor Phys. 1(3): 90-92 (1990). cited by other . Yashiki et al., "Dual mass spectrometry of trifluoroacetyl derivatives of opioid bases" GC-MS News 13(4): 101-106 (1985). cited by other . Yassen A. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers. Clinical Pharmacokinetics 2007; 46(11):965-80. cited by other . Yaster et al., "Epidural analgesia in the management of severe vaso-occlusive sickle cell crisis" Pediatrics 93(2): 310-315 (1994). cited by other . Yaster et al., "The management of pain in sickle cell disease" Pediatr. Clin. North Am. 47(3): 699-710 (2000). cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 08/939,068 to Reder et al., filed Sep. 29, 1997. cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 09/311,997 to Reder et al., filed Jun. 14, 1999. cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 09/756,419 to Reder et al., filed Jan. 18, 2001. cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 10/033,056 to Reder et al., filed Dec. 27, 2001. cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 10/394,425 to Kaiko et al., filed Mar. 27, 2003. cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 10/402,288 to Reder et al., filed Mar. 28, 2003. cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 10/476,601 to Tavares et al., filed Nov. 20, 2003. cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 10/736,043 to Reidenberg et al., filed Dec. 15, 2003. cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 10/736,049 to Reidenberg et al., filed Dec. 15, 2003. cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 11/033,106 to Reder et al., filed Jan. 11, 2005. cited by other . Office Actions issued in the prosecution of U.S. Appl. No. 11/033,107 to Reder et al., filed Jan. 11, 2005. cited by other . Office Actins issued in the prosecution of U.S. Appl. No. 11/033,108 to Reder et al., filed Jan. 11, 2005. cited by other . Catapres TTS.RTM. Product Information, Physicians' Desk Reference 1998, pp. 610-612. cited by other . Climara.RTM. Product Information, Physicians' Desk Reference 1998, pp. 672-6. cited by other . Kuhlman, Jr., et al., Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. Oct. 1996;20(6):369-78. cited by other . McQuinn, R.L. et al., Sustained oral mucosal delivery in human volunteers of buprenorphine from a thin non-croding mucoadhesive polymeric disk. Journal of Controlled Release 1995, 34:243-50. cited by other . Roy et al., Transdermal Delivery of Buprenorphine through Cadaver Skin. J Pharma Sci 1994, 83(2):126-30. cited by other . Sadee et al., Buprenorphine: Differential interaction with opiate receptor subtypes in vivo. The Journal of Pharmacology and Experimental Therapeutics, Copyright .COPYRGT. 1982, 223(1):157-62. cited by other . Van Buskirk et al, Scale-up of adhesive transdermal drug delivery systems. Pharmaceutical Research 1997, 14(7). cited by other . Wilding et al., Pharmacokinetic evaluation of transdermal buprenorphine in man. International Journal of Pharmaceutics 1996, 132:81-7. cited by other . Ashcroft et al., Buprenorphine TDS: Comparison with sublingual buprenorphine in osteoarthritic pain. 10.sup.th World Congress on Pain, Aug. 19, 2002 Abstract 510-P144. cited by other . Becker et al., Transdermal buprenorphine: Abuse potential assessment in non-opioid-dependent volunteers. CPDD Jun. 16-21, 2001 Abstract 40 (w/ PowerPoint presentation). cited by other . Boas et al., Clinical actions of fentanyl and buprenorphine the significance of receptor binding. Br. J. Anaesth. 1985, 57:192-6. cited by other . Buprenorphine Product Photo, Norspan.TM. 5, 10 & 20. cited by other . Capurso et al., Matrix transdermal technology: focus on a buprenorphine transdermal system. ASHP Midyear Clinical Meeting, Dec. 2001, p. 231D Abstract (w/ PowerPoint presentation). cited by other . Colucci, History of Buprenorphine. PowerPoint presentation presented in Dec. 2002. cited by other . El-Tahtawy et al., 7-Day bioavailability of buprenorphine from a novel transdermal system in demographic subgroups. 13.sup.th Annual ACCP Meeting Abstracts, Sep. 23-25, 2001, p. 1027, Abstract 56 (w/ PowerPoint presentation). cited by other . Friend et al., Simple alkyl esters as skin permeation enhancers. J. Controlled Release 1988 9:33-41. cited by other . Friend et al., Transdermal delivery of levonorgestrel I: Alkanols as permeation enhancers in vitro, Controlled Release 1988 7:243-50. cited by other . Hale et al., Analgesic efficacy of buprenorphine transdermal system vs. Oxy/APAP in patients with chronic low back pain. The Gerontologist, vol. 41, Special Issue Oct. 1, 2001, Program Abstracts from the Gerontological Society of America 54.sup.th Annual Scientific Meeting, Nov. 15-18, 2001, p. 25 (w/ PowerPoint presentation first presented on May 7, 2002 and revised on Oct. 30, 2002). cited by other . Hale et al., Dose proportionality and the dose response of buprenorphine transdermal system in patients with chronic pain. 13.sup.th Annual ACCP Meeting Abstracts, Sep. 23-25, 2001, p. 1027, Abstract 58 (w/ PowerPoint presentation). cited by other . Hale et al., Long-term use of buprenorphine transdermal system (BTDS) in patients with chronic pain. PowerPoint presentation presented May 2002. cited by other . Hale et al., Treatment of patients with chronic low back pain with buprenorphine transdermal systems (BTDS) compared with hydrocodone/acetaminophen. National Clinical Symposium of the American College of Nurse Practitioners, Oct. 20, 2001 Abstract (w/ PowerPoint presentation). cited by other . Jaffe et al., Opioid Analgesics and Antagonists. The Pharmacological Basis of Therapeutics (8.sup.th ed. Pergamon Press) 1990, Chap. 21, pp. 485-521. cited by other . Jeal et al., Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs, Jan. 1997, 53(1):109-38. Review. cited by other . Kaiko et al., Transdermal buprenorphine. Memorial Sloan Kettering Manuscript, Chapter 15 (w/ PowerPoint Final presentation presented May, 2, 2003). cited by other . Lasseter et al., Systemic pharmacokinetic (PK) Study of buprenorphine (B) in mild to moderate chronic hepatic impairment (CHI). Amer. Society for Clinical Pharmacology and Therapeutics 69(2) 2 (P1-4) Feb. 2001 Abstract (w/ PowerPoint presentation presented Mar. 2001). cited by other . Marquardt et al., Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother Oct. 1995, 29(10):969-71. cited by other . Muller et al., Intra--and postoperative interactions between the 2 opioid fentanyl and buprenorphine. Anaesthesist. Apr. 1986, 35(4):219-25 (in German, w/ English abstract). cited by other . Noveck et al., Pharmacokinetics of buprenorphine transdermal system (BTDS 10) employing the LPS pyrogen model. Clinical Pharmacology & Therapeutics 69(2):3 200 2001 Abstract P1-7 (w/ PowerPoint presentation). cited by other . Payne et al., Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs. Apr. 6, 1995, Suppl 3:50-3. cited by other . Peng et al., A review of the use of fentanyl analgesia in the management of acute pain in adults. Anaesthesiology 1999, 90:576-99. cited by other . Reidenberg et al., Absolute bioavailability of a novel buprenorphine transdermal system (BTDS) applied for 7 days. J. Clin Pharmacol. 41(9) 2001 Abstract 55 (w/ PowerPoint presentation presented in the ACCP Meeting, Sep. 2001). cited by other . Reidenberg et al., Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to 7 days. Abstract 13.sup.th Annual ACCP Meeting, Sep. 23-25, 2001, p. 1027 Abstract 57 (w/ PowerPoint presentation). cited by other . Reidenberg et al., Pharmacokinetics and safety of buprenorphine transdermal system (BTDS) for 7-Day application comparing healthy elderly and young adult subjects. Am Pain Soc, 19.sup.th Ann. Sci. Meet., Nov. 2-5, 2000 Abstract 776 (w/ PowerPoint presentation). cited by other . Reidenberg et al., Physiologic effects of buprenorphine transdermal system (BTDS) dose escalation in the young, healthy elderly and elderly hypertensive subjects, FASEB J. 15(4), Mar. 2001 Abstract 457.3 (w/ PowerPoint presentation presented Apr. 2001). cited by other . Roy et al., "Controlled transdermal delivery of fentanyl: characterization of pressure-sensitive adhesives for matrix patch design," J Pharm Sci. May 1996, 85(5):491-5. cited by other . Sandler et al., A Double-blind, placebo--controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory, and pharmacokinetic effects, Anesthesiology Nov. 1994, 81(5):1169-80; discussion 26A. cited by other . Spyker et al., Effectiveness and safety of buprenorphine transdermal system (BTDS) compared with hydrocodone/acetaminophen in the treatment of patients with chronic back pain. J. Pain 2002 3(Suppl. 1):14 Abstract 653 (w/ PowerPoint presentation). cited by other . Spyker et al., Effectiveness of buprenorphine transdermal system (BTDS) compared with oxycodone/acetaminophen and placebo in the treatment of patients with chronic back pain. Morial Convention Center, Oct. 15, 2001 Abstract (w/ PowerPoint presentation). cited by examiner . Spyker et al., Transdermal buprenorphine system (BTDS) in patient-controlled Analgesia (PCA). PowerPoint presentation presented Mar. 2000. cited by examiner . Spyker et al., Analgesic efficacy and safety of buprenorphine transdermal system (BTDS) in patients with osteoarthritis. The Journal of Pain 3(2, Suppl. 1):12 Abstract 645(w/ PowerPoint presentation). cited by examiner . Spyker et al., Effect Size (ES) Meta-analysis Approach to Noninferioity Clinical Pharmacology & Therapeutics 69(2):33 Abstract PII-3 (w/ PowerPoint presentation presented Mar. 5, 2001). 0. cited by examiner . Transtec Summary of Product Characteristics, Oct. 2003. cited by examiner . Ashcroft et al., Buprenorphine TDS: Comparison with sublingual buprenorphine in osteoarthritic pain. 10.sup.th World Congress on Pain, Aug. 19, 2002 Abstract 510-P144. cited by examiner . Becker et al., Transdermal buprenorphine: Abuse potential assessment in non-opioid-dependent volunteers. CPDD Jun. 16-21, 2001 Abstract 40 (w/ PowerPoint presentation). cited by examiner . Boas et al., Clinical actions of fentanyl and buprenorphine the significance of receptor binding. Br. F. Anaesth. 1985, 57:192-6. cited by examiner . Hale et al., Analgesic efficacy of buprenorphine transdermal systems vs. Oxy/APAP in patients with chronic low back pain. The Gerontologist from the Gerontological Society of America 54.sup.th Annual Scientic Meeting, Nov. 15-18, 2001, p. 25 (w/ PowerPoint presentation first presented on May 7, 2002 and revised on Oct. 30, 2002). cited by examiner . Kaiko et al., Transdermal burenorphine. Memorial Sloan Kettering Manuscript, Chapter 15 (w/ PowerPoint Final presentation presented May, 2, 2003). cited by examiner . Lasseter et al., Systemic pharmacokinetic (PK) Study of burenorphine (B) in mild to moderate chronic hepatic impairment (CHI). Amer. Society for Clinical Pharmacology and Therapeutics 69(2) 2 (P1-4) Feb. 2001 Abstract (w/ PowerPoint presentation presented Mar. 2001). cited by examiner . Noveck et al., Pharmacokinetics of burenorphine transdermal system (BTDS 10) employing the LPS pyrogen model. Clinical Pharmacology & Therapeutics 69(2):3 200 2001 Abstract P1-7 (w/ PowerPoint presentation). cited by examiner . Reidenberg et al., Daily pharmacokinetic performance of a burenorphine transdermal system (BTDS) for up to 7 days. Abstract 13.sup.th Annual ACCP Meeting, Sep. 23-25, 2001, p. 1027 Abstract 57 (w/ PowerPoint presentation). cited by examiner . Sandler et al., A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory, and pharmacokinetic effects. Anesthesiology Nov. 1994, 81(5): 1169-80; discussion 26A. cited by other . Spyker et al., Analgesic efficacy and safety of buprenorphine transdermal system (BTDS) in patients with osteoarthritis. The Journal of Pain 3(2, Suppl. 1):12 Abstract 645(w/ PowerPoint presentation). cited by other . Spyker et al., Effectiveness of buprenorphine transdermal system (BTDS) compared with oxycodone/acetaminophen and placebo in the treatment of patients with chronic back pain. Morial Convention Center, Oct. 15, 2001 Abstract (w/ PowerPoint presentation). cited by other . Spyker et al., Effectiveness and safety of buprenorphine transdermal system (BTDS) compared with oxycodone/acetaminophen and placebo in the treatment of patients with chronic back pain. J. Pain 2002 3(Suppl. 1):14 Abstract 653(w/ PowerPoint presentation). cited by other . Spyker et al., Effect Size (ES) Meta-analysis Approach to Noninferioity Clinical Trials. Clinical Pharmacology & Therapeutics 69(2):33 Abstract PII-3 (w/ PowerPoint presentation presented Mar. 5, 2001). cited by other . Adriaensen et al., A long-term open, clinical and pharmacokinetic assessment of sublingual buprenorphine in patients suffering from chronic pain. Acta Anaesthesiol Belg. Mar. 1985;36(1):33-40. cited by other . Amass et al. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994; 13:33-45. cited by other . Amass et al., Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci. 1994;54:1215-28. cited by other . Amass et al., Detectability of buprenorphine dose alternations in opioid-dependence humans. NIDA Res Monogr. 1993; 132-335. cited by other . Arditti et al., [Buprenorphine abuse in a series of 50 drug addicts hospitalized at a drug dependence evaluation hospital center of Marseille] Therapie. 1992; 47:561-2. [in French w/ English transl]. cited by other . Banerjee et al., Haematological changes in buprenorphine-treated mice. Folia Biol (Krakow). 1997;45(3-4):157-62. cited by other . Banks. Overdosage of buprenorphine: case report. N Z Med J. 1979; 89:255-6. cited by other . Banys et al. An open trial of low dose buprenorphine in treating methadone withdrawal. J Subst Abuse Treat. 1994; 11:9-15. cited by other . Barrett et al. The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. Br J Clin Pharmacol. Sep. 1993;36(3):215-9. cited by other . Barron et al. Prenatal buprenorphine exposure and sexually dimorphic nonreproductive behaviors in rats. Pharmacol Biochem Behav. Oct. 1997;58(2):337-43. cited by other . Basu et al. Buprenorphine dependence: a new addiction in India. Disabil Impair. 1990: 3:142-6. cited by other . Baumevieille et al. Abuse of prescription medicines in southwestern France. Ann Pharmacother 1997: 31:847-50. cited by other . Bedi et al. Abuse Liability of Buprenorphine--A study Among Experienced Drug Users. Indian J Physiol. Pharmacol. 1998;42(1), 95-100. cited by other . Benos. [A case of secondary buprenorphine (Temgesic.RTM.) dependence] Der Nervenarzt. 1983;54:259-61. [in German w/ English transl]. cited by other . Biagini et al., Evaluation of cutaneous responses and lung function from exposure to opiate compounds among ethical narcotics-manufacturing workers. J Allergy Clin Immunol. Jan. 1992;89(1 Pt 1):108-18. cited by other . Bickel et al. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988;43:72-8. cited by other . Bickel et al. A clinical trial of buprenorphine: 1. Comparison with methadone in the detoxification of heroin addicts. II. Examination of its opioid blocking properties. NIDA Res Monogr. 1987;76:182-8. cited by other . Bickel et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther. Oct. 1988;247(1):47-53. cited by other . Bickel et al. Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacology 1995; 3:477-89. cited by other . Bickel et al. Effects of adding behavioral treatmment to opioid detoxification with buprenorphine. J Consult Clin Psychol. Oct. 1997;65(5):803-10. cited by other . Bigelow (w/ Introduction by Blaine). Assessment of buprenorphine in a drug discrimination procedure in humans. Buprenorphine: An alternative Treatment for Opioid Dependence. NIDA Res Monogr. 1992;121:28-37. cited by other . Bigelow et al. Abuse liability assessment of buprenorphine-naloxone combinations. NIDA Res Monogr. 1987;76:145-9. cited by other . Bigelow. Buprenorphine: Combatting drug abuse with a unique opioid. 1995;(Foreword):xi-xiii. cited by other . Bigelow. Human drug abuse liability assessment: opioids and analgesics. Br J Addict. 1991; 86: 1615-23. cited by other . Blaine. Introduction. NIDA Res. Monogr. 1992; 1-4. cited by other . Budd. High dose buprenorphine for postoperative analgesia. Anaesthesia. Sep. 1981;36(9):900-3. cited by other . Bullingham et al. Buprenorphine kinetics. Clin Pharmacol Ther. Nov. 1980;28(5):667-72. cited by other . Bullingham et al. Clinical phamacokinetics of narcotic agonist-antagonist drugs. Clin Pharmacokinet. Jul.-Aug. 1983;8(4):332-43. cited by other . Bullingham et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol. May 1982;13(5):665-73. cited by other . Buprenorphine is now a controlled drug. Drug Ther Bull. Oct. 16, 1989;27(21):84. cited by other . Buprenorphine RTECS Info. In: RTCES Registry No. 52485-79-7. Jan. 13, 2000. cited by other . Buprenorphine RTECS Record. In: RTCES Registry No. 52485-79-7. Apr. 25, 2000. cited by other . Carl et al. Pain relief after major abdominal surgery: a double-blind controlled comparison of sublingual buprenorphine, intramuscular buprenorphine, and intramuscular meperidine. Anesth Analg. Feb. 1987;66(2): 142-6. cited by other . Cervera et al. [Addiction to buprenorphine] Rev Clin Esp 1989;184:159. Letter. [in Spanish w/ English transl]. cited by other . Cheskin et al. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 1994;36:115-21. cited by other . Clausen et al. Legal opioid consumption in Denmark 1981-1993. Eur. J Clin Pharmacol. 1995;48(5):321-5. cited by other . Cowan et al. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol. Aug. 1977;60(4):537-45. cited by other . Cowan et al. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol. Aug. 1977;60(4)547-54. cited by other . Cowan. Update on the general pharmacology of buprenorphine. Buprenorphine: Combatting Drug Abuse with a Unique Opioid. 1995;31-47. cited by other . D'Arcy. [Drug reactions and interactions after drug reactions and interactions] J Pharm Belg. Sep.-Oct. 1988;43(5):401-4. [in French w/ partial English transl]. cited by other . Davies et al. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet. Dec. 1996;31(6):410-22. cited by other . Dertwinkel et al. Clinical status of opioid tolerance in long-term therapy of chronic noncancer pain. In: Progress in Pain Research and Management. Opioid Sensitivity of Chronic Noncancer Pain. Kalso et al., eds. 1999; 14:129-41. cited by other . Diamant et al. Outpatient opiate detoxification treatment with buprenorphine. Preliminary investigation. Eur Addict Res. 1998;4:198-202. cited by other . Dini et al. [Controlled study of the analgesic effect and tolerability of buprenorphine in cancer patients] Minerva Med. Jan. 28, 1986;77(3-4):93-104. [in Italian w/ English abstract]. cited by other . Dum et al. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol. Nov. 1981;74(3):627-33. cited by other . Eissenberg et al. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther. 1996: 276:449-59. cited by other . Eissenberg et al. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend. Apr. 14, 1997;45(1-2):81-91. cited by other . Faroqui et al. Buprenorphine, benzodiazepines and respiratory depression. Anaesthesia. Oct. 1983;38(10):1002. cited by other . Fincham. Cardiopulmonary arrest and subsequent death after administration of buprenorphine in an elderly female: a case report. J. Geriatric Drug Ther. 1989;3(3):103-5. cited by other . Fischer et al. Buprenorphine maintenance in pregnant opiate addicts. Eur Addict Res. 1998;4(Suppl 1):32-6. cited by other . Forth. [Another analgesic unmasked as an addictive substance: a vicious circle] MMW Munch Med Wochenschr. Sep. 30, 1983;125(39):834. [in German w/ English transl]. cited by other . Francaviglia et al. Subarachnoid buprenorphine administered by implantable micropumps. Acta Neurochir (Wien). 1990;102(1-2):62-8. cited by other . Franklin et al. Risk assessment in dermatotoxicology. In: Marzulli et al. (Eds.) Dermatotoxicology (4.sup.th ed.) 1991. 1991;30:713-47. cited by other . Fraser. Clinical toxicology of drugs used in the treatment of opiate dependency. Clinics in Laboratory Medicine. Jun. 1990;10(2):375-86. cited by other . Fudala et al. A multi-site efficacy evaluation of a buprenorphine/naloxone product for opiate dependence treatment. NIDA Res Monogr. Problems of Drug Dependent: Proceedings of the 60.sup.th annual Scientific Meeting; 1998:105. cited by other . Fudala et al. Clinical efficacy studies of buprenorphine for the treatment of opiate dependence. Buprenorphine: Combatting Drug Abuse with a Unique Opioid. 1995: 213-39. cited by other . Fudala et al. Outpatient comparison of buprenorphine and methadone maintenance. II. Effects on cocaine usage, retention time in study and missed clinic visits. NIDA Res Monogr. 1991;105:587-8. cited by other . Fudala et al. Use of buprenorphine in the treatment of opioid addiction. II.Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther. 1990; 47:525-34. cited by other . Fujimura et al. Influences of bathing and hot weather on the pharmacokinetics of a new transdermal clonidine. M-5041T. J Clin Pharmacol. Oct. 1996;36(10):892-6. cited by other . Fullerton et al. Prolonged nauseca and vomiting associated with buprenorphine. Pharmacotherapy 1991;11:90-93. cited by other . Gebhart et al. Opiod modulation of visceral pain. In: Progress in Pain Research and Management. Opioid Sensitivity of Chronic Noncancer Pain. Kalso et al., eds. 1999;225-35. cited by other . Gould. Buprenorphine causes pulmonary edema just like all othr mu-opioid narcotics. Upper airway obstruction, negative alveolar pressure. Chest. May 1995;107(5):1478. cited by other . Gourlay. Different opioids--same actions? In: Progress in Pain Research and Management. Opioid Sensitivity of Chronic Noncancer Pain. Kalso et al., eds. 1999; 14:97-115. cited by other . Grond et al. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. Jan. 2000;38(1):59-89. cited by other . Guilbaud et al. Antinociceptive effect of opioid substances in different models of inflammatory pain. In: Progress in Pain Research and Management. Opioid Sensitivity of Chronic Noncancer Pain. Kalso et al., eds. 1999; 14:201-23. cited by other . Hand et al. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth. Mar. 1990;64(3):276-82. cited by other . Hand et al. Radioimmunoassay of buprenorphine in urine: studies in patients and in a drug clinic. J Anal Toxicol. Mar.-Apr. 1989;13(2):100-4. cited by other . Heel et al. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1979;17:81-110. cited by other . Henrion. [Assessment of the effectiveness of measures taken in France to reduce the risk of intravenous heroin addiction] Bull Acad Natl Med. Jun-Jul. 1997; 181(6):1177-85; discussion 1186-9. [in French w/ English transl]. cited by other . Hernandez-Mora et al. [Paroxysmal atrial fibrillation after ingestionof buprenorphine.] Rev Clin Esp. Jun. 1988;183(2):99-100. [in Spainish w/ English transl]. cited by other . Hirschauer et al. [Is buprenorphine hepatotoxic?] Gastroenterol Clin Biol. Jun. 1989;13(6-7):636. [in French w/ English transl]. cited by other . Holdsworth et al. Transdermal fentanyl disposition in elderly subjects. Gerontology. 1994;40(1):32-7. cited by other . Holmes. Buprenorphine side effects. N Z Med J. Mar. 14, 1984;97(751):166. cited by other . Hoskin et al. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991;41:326-44. cited by other . Huguet-Levet. [Buprenorphine: its ambiguity] Ann Pharm Fr. 1995;53(3):124-30. [in French w/ English transl]. cited by other . Jamison. Comprehensive pretreatment and outcome assessment for chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage. Apr. 1996;11(4):231-41. cited by other . Jasinski et al. Abuse liability assessment in human subjects. Trends Pharmacol Sci. 1984;5:196-200. cited by other . Jasinski et al. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978:35:501-16. cited by other . Jasinski et al. Laboratory studies of buprenorphine in opioid abusers. In: Cowan A, Lewis J W, eds. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss. 1995:189-211. cited by other . Jasinski et al. Progress report from the NIDA Addiction Research Center, Baltimore, Maryland. NIDA Res Monogr. Mar. 1984;49:69-76. cited by other . Jasinski et al. Progress report of the NIDA Addiction Research Center. NIDA Res Monogr. 1982;41:45-52. cited by other . Jasinski et al. Progress report of the NIDA Addiction Research Center. Baltimore, Maryland, 1982. NIDA Res Monogr. Apr. 1983;43:92-8. cited by other . Jasinski et al. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther. 1989;45:513-9. cited by other . Johnson et al. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-5. cited by other . Kalso. Route of opioid administration--does it make a difference ? In: Progress in Pain Research and Management. Opioid Sensitivity of Chronic Noncancer Pain. Kalso et al., eds. 1999; 14:117-28. cited by other . Kareti et al. Effects of buprenorphine, a new narcotic agonist-antagonist analgesic on the EEG, power spectrum and behavior of the rat. Neuropharmacology. Feb. 1980;19(2):195-201. cited by other . Keup et al. [Potential for buprenorphine abuse] MMW Munch Med Wochenschr. Sep. 30, 1983:125(39):835-7. [in German w/ English transl]. cited by other . Keup. [Buprenorphine (Temgesic.RTM.) abuse and dependence] Suchtgefahren. 1983;29:193-4. [in German w/ English transl]. cited by other . Lange et al. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend. Aug. 1990;26(1):19-28. cited by other . Law et al. The feasibility of abrupt methadone-buprenorphine transfer in Bitish opiate addicts in an outpatient setting. Addition Bio. 1997;2:191-200. cited by other . Leander. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacol. 1987;26:1445-7. cited by other . Leander. Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice. Eur J Pharmacol. Jul. 14, 1988;151(3):457-61. cited by other . Lewis et al. Buprenorphine--background to its development as a treatment for opiate dependence. NIDA Res Monogr. 1992;121:5-11. cited by other . Lewis. Buprenorphine. Drug Alcohol Depend. 1985. 14:363-72. cited by other . Lewis. Clinical pharmacology of buprenorphine in relation to its use as an analgesic. Buprenorphine: Combatting Drug Abuse with a Unique Opioid. 1995;151-63. cited by other . Lewis et al. The Pharmacology and abuse potential of buprenorphine: a new antagonist analgesic. Advances in substance abuse 1983;3:103-54. cited by other . Ling et al. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. May 1996;53(5):401-7. cited by other . Ling et al. Buprenorphine maintenance treatment of opiate dependence, a multicenter, randomized clinical trial. Addiction. 1998;93:475-86. cited by other . Ling et al. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study. Arch Gen Psychiatry. Jun. 1976;33(6):709-20. cited by other . Ling et al. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs. Apr.-Jun. 1994;26(2):119-28. cited by other . Litchfield. Buprenorphine in oral surgery. A comparison with fentanyl. SAAD Dig. Oct. 1986;6(8):182-6. cited by other . Liu et al. Rapid detoxification of heroin dependence by buprenorphine. Acta Pharmacol Sin. 1997;18:112-4. cited by other . Lizasoain et al. Buprenorphine: bell-shaped dose-response curve for its antagonist effects. Gen Pharmacol. 1991;22(2):297-300. cited by other . Lloyd-Jones et al. Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons. Eur J Drug Metab Pharmacokinet. 1980;5(4):233-9. cited by other . Macdonald et al. Psychomotor effects of ketorolac in comparison with buprenorphine and diclofenac. Br J Clin Pharmacol. 1989;27:453-9. cited by other . Mackenzie et al. Influence of pretreatment with a monoamine oxidese inhibitor (Phenelzine) on the effects of buprenorphine and pethidine in the conscious rabbit. Br J Anaesth. 1988;60:216-21. cited by other . Marquet et al. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther. 1997;62:569-71. cited by other . Marquet et al. [In utero exposure to Subutex induces no or mild withdrawal syndromes in the newborn] Therapie. 1998;53:178. [in German w/ English abstract]. cited by other . Martin. History and development of mixed opioid agonist, partial agonist and antagonists. Br J Clin Pharmacol. 1979;7:273S-9S. cited by other . Martin et al. The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197:517-32. cited by other . Max et al. Single-dose analgesic comparisons. Advances in pain research and therapy. 1991;18:55-95. cited by other . McQuay et al. Buprenorphine kinetics. Advances in Pain Res and Ther. 1986. 8:271-83. cited by other . McQuay et al. Buprenorphine kinetics in humans. In: Buprenorphine: Combatting Drug Abuse with a Unique Opioid. 1995;137-47. cited by other . McQuay et al. Clinical effects of buprenorphine during and after operation. Br J Anaesth. Oct. 1980;52(10):1013-9. cited by other . McQuay et al. Delayed respiratory depression. A case report and a new hypothesis. Acta Anaesthesiol Belg. 1979;30 Suppl:245-7. cited by other . Mello et al. Behavioral pharmacology of buprenorphine. Drug Alcohol Depend. Feb. 1985;14(3-4):283-303. cited by other . Mello et al. Buprenorphine effects on human heroin self-administration: an operant analysis. J Pharmacol Exp Ther. 1982:223:30-9. cited by other . Mello et al. Buprenorphine self-administration by rhesus monkey. Pharmacol Biochem Behav. 1981;15:215-25. cited by other . Mello et al. Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science. 1989;245:859-62. cited by other . Mello et al. Buprenorphine suppresses heroin use by heroin addicts. Science. 1980;207:657-9. cited by other . Mello et al. Buprenorphine's effects on cocaine self-administration: preclinical studies. In: Buprenorphine Combatting Drug Abuse With A Unique Opioid. 1995;249-50. cited by other . Mendelson et al. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37:31-7. cited by other . Mendelson et al. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry. 1997;41:1095-101. cited by other . Mendelson et al. Buprenorphine attenuates the effects of cocaine on adrenocorticotropin (ACTH) secretion and mood states in man. Neuropsychopharmacology. 1992;7:157-62. cited by other . Mendelson et al. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther. Jul. 1996;60(1):105-14. cited by other . Mendelson et al. Human laboratory studies of buprenorphine. NIDA Res Monogr. 1992;121:38-60. cited by other . Mitaka et al. Comparison of hemodynamic effects of morphine, butorphanol, buprenorphine and pentazocine on ICU patients. Bull Tokyo Med Dent Univ. Jun. 1985;32(2):31-9. cited by other . Moa et al. Sublingual buprenorphine as postoperative analgesic: a double-blind comparison with pethidine. Acta Anaesthesiol Scand. 1990;34:68-71. cited by other . Mok et al. Multidose/observational, comparative clinical analgetic evaluation of buprenorphine. J Clin Pharmacol. Jul. 1981;21(7):323-9. cited by other . Moore et al. Reversal of postoperative hyperglycaernia by buprenorphine. Lancet. Sep. 13, 1980;2(8194):597-8. cited by other . Morrison. Psychoactive substance use and related behaviours of 135 regular illicit drug users in Scotland. Drug Alcohol Depend. 1989;23:95-101. cited by other . Mukhtar et al. Cutaneous cytochrome P-450. Drug. Metabolism Revs. 1989;20(204):657-73. cited by other . Mukhtar et al. Cytochrome P-450 dependent metabolism of testosterone in rat skin. Biochem Biophys Res Commun. Jun. 15, 1987;145(2):749-53. cited by other . Nasar et al. An open study of sub-lingual buprenorphine in the treatment of chronic pain in the elderly. Curr Med Res Opin. 1986;10(4):251-5. cited by other . Nigam et al. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat. Jul.-Aug. 1993;10(4):391-4. cited by other . Nizamie et al. Buprenorphine abuse: a case report. Indian J Psychiatry. 1990;32:198-200. cited by other . O'Brien. Drug adiction and abuse. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9.sup.th ed. 1996;Chp. 24:557-577. cited by other . O'Connor et al. Buprenorphine abuse among opiate addicts Brit J Addict. 1988; 83:1085-7. cited by other . O'Connor et al. Rapid and ultrarapid detoxification techniques. JAMA 1998;279:229-34. cited by other . O'Connor et al. Three methods of opioid detoxification in a primary care setting: a randomized trial. Ann Intern Med. 1997;127:526-30. cited by other . O'Neill. The cognitive and psychomotor effects of opioid drugs in cancer pain management. Cancer Surv. 1994;21:67-84. cited by other . Obel et al. Buprenorphine-supplemented anaesthesia. Influence of dose on duration of analgesia after cholecystectomy. Br J Anaesth. Mar. 1985;57(3):271-4. cited by other . Ohtani et al. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine, J Pharmacol Exp Ther. Apr. 1997;28(1):428-33. cited by other . Olley et al. Plasma levels of opioid material in man following sublingual and intravenous administration of buprenorphine: exogenous/endogenous opioid interaction? J Pharm Pharmacol. 1988;40:666-7. cited by other . Opioid agonist-antagonist analgesics. In: WHO Expert Committee on Drug Dependence. 25.sup.th Report, Geneva: World Health Oarganization Technical Report Series; 1989:775 16-24. cited by other . Orwin et al. A double blind comparision of buprenorphine and morphine in conscious subjects following administration by the intramuscular route. Acta Anaesthesiol Belg. 1976;27:171-81. cited by other . Orwin. Pharmacological aspects in man. Pain:vNew Perspect. Meas. Manage. (Symp) 1977:141-59. cited by other . Ouellette et al. Comparison of buprenorphine and morphine: a multicenter, multidose study in patients with severe postoperative pain. Contemp. Surg. 1986; 28:55,57-59,62-64. cited by other . Ouellette. Buprenorphine and morphine efficacy in postoperative pain: a double-blind multiple-dose study. J Clin Pharmacol. Apr. 1982;22(4):165-72. cited by other . Ouellette. Comparison of analgesic activity of buprenorphine hydrochloride and morphine in patients with moderate to severe pain postoperatively. Surg Gynecol.Obstet. Sep. 1984;159(3):201-6. cited by other . Overweg--Van Kintz et al. [Failing pain suppression during sublingual use of buprenorphine] Ned Tijdschr Geneeskd. 1987;131(44)1973-4. [in Dutch w/ English transl]. cited by other . Parran et al. A buprenorphine stabilization and rapid-taper protocol for the detoxification of opioid dependent patients. Am J Addict. 1994;3:306-13. cited by other . Pathre et al. Generalised seizure following sublingual buprenorphine. J Assoc Physicians India. Apr. 1994;42(4):327-8. cited by other . Pausawasdi et al. A comparison of buprenorphine and morphine for immediate postoperative pain relief in Thai patients. J Med Assoc Thai. May 1984;67(5):284-9. cited by other . Pechnick et al. The effects of the acute administration of buprenorphine hydrochloride on the release of anterior pituitary hormones in the rat: evidence for the involvement of multiple opiate receptors. Life Sci. Nov. 18, 1985;37(20):1861-8. cited by other . Pedersen et al. Peroperative bupronorphine: do high dosages shorten analgesia postoperatively? Acta Anaesthesiol Scand. Nov. 1986;30(8):660-3. cited by other . Petti. Postoperative pain relief with pentazocine and acetaminophen: comparison with other analgesic combinations and placebo. Clin Ther. 1985;8(1):126-33. cited by other . Ponsoda et al. The effects of buprenorphine on the metabolism of human hepatocytes. Toxic. In vitro. 1991;5(3):219-24. cited by other . Pontani et al. Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica. Apr. 1985;15(4):287-97. cited by other . Preston et al. Abuse liability studies of opioid agonist-antagonists in humans. Drug Alcohol Depend. 1991;28:49-82. cited by other . Preston et al. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend. Jan. 1991;27(1):7-17. cited by other . Preston et al. Diazepam and methadone interactions in methadone maintenance. Clin Pharmacol Ther. Oct. 1984;36(4):534-41. cited by other . Preston et al. Discrimination of agonist-antagonist opioids in humans trained on two-choice saline-hydromorphone discrimination. J Pharmacol Exp Ther. 1992;261:62-71. cited by other . Preston et al. Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure. J Pharmacol Exp Ther. 1994;271:48-60. cited by other . Preston et al. Drug discrimination in human postaddicts: agonist-antagonist opioids. J Pharmacol Exp Ther. 1989;250:184-96. cited by other . Preston et al. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend. 1990;25:27-34. cited by other . Price et al. A psychophysical analysis of experimential factors that selectively influence the affective dimension of pain. Pain. Apr. 1980;8(2):137-49. cited by other . Quigley et al. A case of buprenorphine abuse. Med J Aust. 1984; 140:425-6. cited by other . Rainey. Abuse of buprenorphine. N Z Med J. 1986; 99:72. cited by other . Regini et al. [Buprenophine withdrawal syndrome in a neonate. Which treatment?] Ped Med Chir. 1998; 20:67-9. [in Italian with English transl]. cited by other . Reisine et al. Opioid analgesics and antagonists. In: Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's The pharmacological basis of therapeutics. 9.sup.th ed. 1996; Chp. 23:521-55. cited by other . Reisinger. [Value of comparing buprenorphine with methadone] Ann Med Interne (Paris). Nov. 1994;145 Suppl 3:23-5. [in French w/ English transl]. cited by other . Reisinger. Buprenorphine as new treatment for heroin dependence. Drug Alcohol Depend. Dec. 1985;16(3):257-62. cited by other . Reisinger. Results from experience with buprenorphine replacement in outpatients in Belgium. Ann. Med. Interne. 1994;145(Supp.3):46-47. cited by other . Reisinger. Treatment of four pregnant heroin addicts with buprenorphine: history and outcome. NIDA Res Monogr 1995;162-261. cited by other . Report of the commission on the evaluation of pain. In: Soc. Security Bull. 1986. cited by other . Reynaud et al. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998;93:1385-92. cited by other . Richard et al. [Virtiginous syndrome: side effect of buprenorphine?] Cah Anesthesiol. 1988; 36:641-2. [in French with English transl]. cited by other . Richert et al. [Drug dependence on buprenorphine] MMW Munch Med Wochenschr 1983; 125:1195-8. [in German w/ English transl]. cited by other . Risbo et al. Sublingual buprenorphine for premedication and postoperative pain relief in orthopaedic surgery. Acta Anaesthesiol Scand. Feb. 1985;29(2):180-2. cited by other . Robbie. A trial of sublingual buprenorphine in cancer pain. Br J Clin Pharmacol. 1979;7 Suppl 3:315S-317S. cited by other . Robertson et al. Buprenorphine: dangerous drug or overlooked therapy? Br Med J. 1986:292-1465. cited by other . Robinson et al. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington. new Zealand. Drug Alcohol Depend. 1993; 33:81-6. cited by other . Rolandi et al. Changes in pituitary secretion induced by an agonist-antagonist opioid drug. Acta Endocrinol (Copenh). Nov. 1983;104(3):257-60. cited by other . Rosen et al. Buprenorphine: duration of blockade of effects of intramuscular hydromorphine. Drug Alcohol Depend. 1994;35:141-9. cited by other . Rosen et al. Effects of acute buprenorphine on responses to intranasal cocaine: a pilot study. Am J Drug Alcohol Abuse. 1993;19:451-64. cited by other . Rosenfeldt et al. Haemodynamc effects of buprenorphine after heart surgery. Br Med J. Dec. 9, 1978;2(6152):1602-3. cited by other . Rothman et al. Buprenorphine: a review of the binding literature. In: Buprenorphine: Combatting Drug Abuse with a Unique Opioid. 1995;19-29. cited by other . Saarialho-Kere et al. Psychomotor, respiratory, and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. Eur J Clin Pharmacol. 1987; 33:139-46. cited by other . Sakol et al. Buprenorphine and temazepam abuse by drug takers in Glasgow--an increase. Brit J Addict. 1989;84:439-41. cited by other . San et al. [Prevalence of buprenorphine consumption in heroin addicts undergoing treatment] Med Clin (Barc). 1989; 93:645-8. [in Spanish w/ English transl]. cited by other . San et al. Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. Br J Addict. Jan. 1992;87(1):55-62. cited by other . San et al. Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: results from cross-sectional studies in 1988 and 1990. Addiction. 1993; 88:1341-9. cited by other . San Molina et al. [Addiction to buprebnorphine] Rev Clin Esp. 1987;181:288-9. [in Spanish w/ English transl]. cited by other . Schmidt et al. Postoperative pain relief with naloxone. Severe respiratory depression and pain after high dose buprenorphine. Anaesthesia. 1985;40:583-6. cited by other . Schottenfeld et al. Buprenorphine vs. methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54:713-20. cited by other . Schuh et al. Buprenorphine, morphine, and naloxone effects during ascending morphine maintenance in humans. J Pharmacol Exp Ther. 1996; 278:836-46. cited by other . Sear et al. Buprenorphine for postoperative analgesia. Br J Anaesth. Jan. 1979;51(1):71. cited by other . Segal et al. Buprenorphine: what interests the national institute on drug abuse? Buprenorphine: In: Combatting Drug Abuse with a Unique Opioid. 1995;309-20. cited by other . Segui et al. [Buprenorphine comsumption, an indicator of poor prognosis in the course of drug dependencies] Actas Luso Esp Neurol Psiquiatr Cienc Afines. Jan.-Feb. 1992;20(1):17-22. [in Spanish w/ English transl]. cited by other . Segui et al. [Data regarding buprenorphine consumption by drug-addicted individuals] Rev Clin Esp. 1989; 185:271-2. [in Spanish with English transl]. cited by other . Segui et al. [Prevalence of buprenorphine consumption in a sample of outpatient drug abusers] Rev Clin Esp. Jun. 1991;189(1):14-7. [in Spanish w/ English transl]. cited by other . Segui et al. [Subgroups of addicted buprenorphine-consuming patients] An Med Interna. Jan. 1991;8(1):18-22. [in Spanish w/ English transl]. cited by other . Sekar et al. Buprenorphine, benzodiazepines and prolonged respiratory depression. Anaesthesia. 1987;42:567-8. cited by other . Seow et al. Buprenorphine: a new maintenance opiate? Med J Aust. Apr. 14, 1986; 144(8):407-11. cited by other . Sganzerla et al. Analgesia and hemodynamic effects of buprenorphine in acute infarction of the heart, Jpn Heart J. Jan. 1987;28(1):63-71. cited by other . Shannon et al. Morphine-like discriminative stimulus effects of buprenorphine and demethoxbuprenorphine in rats: quantitative antagonism by naloxone. J Pharmacol Exp Ther. 1984; 229:768-74. cited by other . Shuster. Fluoroquinolones and tendon rupture or tendinitis. Buprenorphine-induced hypertension and tachycardia: rare but serious. Hospital Pharmacy. 1996;31(1)41-2. cited by other . Singh et al. Cases of buprenorphine abuse in India. Acta Psychiatr Scand. 1992;86:46-8. cited by other . Sjovall. Use of midazolam and buprenorphine in combination anaesthesia. Ann Clin Res. Aug. 1983;15(4):151-5. cited by other . Spitzer et al. Scientific approach to the assessment and management of activity-related spinal disorders. Spine. 1987;12(7):S9-S59. cited by other . Staritz. Pharmacology of the sphineter of Oddi. Endoscopy. Aug. 1988;20 Suppl 1:171-4. cited by other . Stellato et al. Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release. Anesthesiology. Nov. 1992;77(5):932-40. cited by other . Stewart. Effect of scheduling of buprenorphine (Temgesic) on drug abuse pattern in Glasgow. BMJ. Apr. 20, 1991;302(6782):969. cited by other . Stinchcomb et al. Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. Pharm Res. Oct. 1996;13(10):1519-23. cited by other . Strain et al. Acute effects of buprenorphine, hydromorphone, and naloxone in mathadone-maintained volunteers. J Pharmacol Exp Ther. 1992:261:985-93.. cited by other . Strain et al. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther. 1995;272:628-38. cited by other . Strain et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1025-30. cited by other . Strain et al. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacol. 1997;129:329-38. cited by other . Strang. Abuse of buprenorphine (Temgesic) by snorting. BMJ. Apr. 20, 1991; 302(6782):969. cited by other . Strang. Abuse of buprenorphine. Lancet. Sep. 28, 1985;2(8457):725. cited by other . Streisand. Transdermal-mucosal sedative and analgesic delivery. West. J Med. 1990;153:310. cited by other . Su. Further demonstration of .kappa. opioid binding sites in the brain: evidence of heterogeneity. J Pharmacol Exp. Ther. 1985;232:144-8. cited by other . Summerfield et al. Buprenorphine in end stage renal failure. Anaesthesia. Sep. 1985;40(9):914. cited by other . Swain et al. Primary addiction study. UM952. In: Minutes of the Committee on Problems of Drug Dependence. Washington (DC), National Academy of Sciences, National Research Council. 1975;791. cited by other . Tallarida et al. Theory and statistics of detecting synergism between two active drugs: cocaine and buprenorphine. Psychopharmacology (Berl). Oct. 1997;133(4):378-82. cited by other . Tantucci et al. Acute respiratory effects of sublingual buprenorphine: comparison with intramuscular morphine. Int J Clin Pharmacol Ther Toxicol. Jun. 1992;30(6):202-7. cited by other . Tebbett. Analysis of buprenorphine by high-performance liquid chromatography. J Chromatogr. Nov. 22, 1985;347(3):411-3. cited by other . Teoh et al. Acute interactions of buprenorphine with intravenous cocaine and morphine: an investigational new drug phase 1 safety evaluation. Clin Psychopharmacol. 1993;13:87-99. cited by examiner . Teoh et al. Buprenorphine effects on morphine-and cocaine-induced subjective responses by drug-dependent men. J Clin Psychopharmacol. Feb. 1994;14(1):15-27. cited by examiner . Thammakumpee et al. Noncardiogenic pulmonary edema induced by sublingual buprenorphine. Chest. Jul. 1994;106(1):306-8. cited by examiner . Tharp et al. Functional hetergeneity of human mast cells from different anatomic sites: in vitro responses to morphine sulfate. J Allergy Clin Immunol. Apr. 1987;79(4):646-53. cited by examiner . Thorn et al. Prolonged respiratory depression caused by sublingual buprenorphine. Lancet. Jan. 23, 1988;1(8578):179-80. cited by examiner . Tigerstedt et al. Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain. Acta Anaesthesiol Scand. Dec. 1980;24(6):462-8. cited by examiner . Touzeau et al. Benzodiazepines and methadone: a dangerous combination?] Ann Med Interne (Paris). Nov. 1994;145 Suppl 3:19-22. [in French w/ English transl]. cited by examiner . Tracqui et al. [Prison, drugs and death: two deaths due to overdoses in a prison environment] J Med Leg Droit Med. 1998a;41:185-92. [in French w/ English transl]. cited by examiner . Tracqui et al. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol. 1998c;22:430-4. cited by examiner . Uehlinger et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study. Eur Addict Res. 1998;4 Suppl 1:13-8. cited by examiner . Umbricht et al. Safety of bruprenorphine: ceiling for cardio-respiratory effects at high IV doses. NIDA Res Monogr. 1998; 179:225. cited by examiner . Van Loveren et al. Assessment of immunotoxicity of buprenorphine. Lab Anim. Oct. 1994;28(4):355-63. cited by examiner . Vanakoski et al. Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine. Clin Pharmacol Ther. Sep. 1996;60(3):308-15. cited by examiner . Varey. The safety of buprenorphine (Temgesic). N Z Med J. Jan. 24, 1990;103(882):24. cited by examiner . Vargas et al. Buprenorphine: a case of abuse [letter] [in Spanish]. An Med Interna. 1987; 4:366. cited by examiner . Ventafridda et al. Chronic analgesic study on buprenorphine action in cancer pain. Comparison with pentazocine, Arzneimittelforschung. 1983;33(4):587-90. cited by examiner . Vignau. Preliminary assessment of a 10-day rapid detoxification programme using high dosage buprenorphine. Eur. Addict Res 1998; 4 Suppl. 1:29-31. cited by examiner . Villiger. Binding of buprenorphine to opiate receptors. Regulation by guanyl nucleotides and metal ions. Neuropharmacology. Mar. 1984;23(3):373-5. cited by examiner . Vocci. Basis for the recommendation for rescheduling of buprenorphine into Schedule IV of the Controlled Substances Act. FDA Document 2726A; Jul. 31, 1980;1-8. cited by examiner . Waal. Buprenorphine (Temgesic)--new agent of abuse. Tidsskr Nor Laegeforen 1989; 109:1326-7. [in Norwegian w/ English transl]. cited by examiner . Walsh et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569-80. cited by examiner . Walsh et al. The acute effects of high dose buprenorphine in non-dependent humans. NIDA Res. Monogr. 1992;119:245. cited by examiner . Walter et al. Absorption, distribution, metabolism, and excretion of buprenorphine in animals and humans. In: Buprenorphine: Combatting Drug Abuse with a Unique Opiod. 1995;13-35. cited by examiner . Walter et al. Preclinical evaluation of buprenorphine. Research and Clinical Forums. 1997;19(2):17-23. cited by examiner . Wang et al. The study of anagesics following single and repeated doses. J Clin Pharmacol. Feb.-Mar. 1981;21(2):121-5. cited by examiner . Watanabe et al. Rectal absorption and mucosal irritation of rectal gels containing buprenorphine hydrochloride prepared with water-soluble dietary fibers, xanthan gum and locust bean gum. J Controlled Release. 1996;38:29-37. cited by examiner . Weinberg et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther. 1988;44:335-42. cited by examiner . Wiesenfeld-Hallin et al. Opioid sensitivity in antinociception: Role of anti-opioid systems with emphasis on cholecystokinin and NMDA receptors. In: Progress in Pain Research and Management. Opioid Sensitivity of Chronic Noncancer Pain. Kalso et al., eds. 1999; 14:237-52. cited by examiner . Woods et al. Behavioral pharmacology of buprenorphine: issues relevant to its potential in treating drug abuse. NIDA Res Monogr. 1992;121:12-27. cited by examiner . Wright et al. Acute physical dependence in humans: repeated naloxone-precipitated withdrawal after a single dose of methadone. Drug Alcohol Depend. 1991; 27:139-48. cited by examiner . Yanagita et al. Dependence potential of buprenorphine studied in rhesus monkeys. NIDA Res Monogr. 1982;41:208-14. cited by examiner . Zacny et al. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther. 1997;282:1187-97. cited by examiner . Zacny et al. A review of the effects of opioids on psychomotor and cognitive functioning in humans. Experimental and Clin. Psychopharmacol. 1995:3(4):432-66. cited by examiner . Zola et al. Comparative effects and analgesic efficacy of the agonist-antagonist opioids. Drug Intell Clin Pharm. Jun. 1983;17(6):411-7. cited by other . 7.2. Buprenorphine, MNH/PAD/87.11, pp. 29-63 (undated). cited by other . A review of data for the scientific community in preparation for the WHO 2002 critical review of buprenorphine: Scientific, medical and policy support for the continuing control of Buprenorphine in Schedule III of the 1971 Convention on Psychotropic Substance. Dec. 13, 2001 (30 pp.). cited by other . Addendum to a review of data for the scientific community in preparation for the WHO 2002 critical review of buprenorphine: Data on reactions possibly related to abuse of Buprenorphine reported to the WHO collaborating centre for international drug monitoring. Uppsala Sweden and Data on seizures from the NFLIS. Feb. 26, 2002 (11 pp.). cited by other . Agar et al., Buprenorphine: "field trials" of a new drug. Qual Health Res. Jan. 2001;11(1):69-84. cited by other . Annual report on the state of the drugs problem in the European Union by EMCDDA. 1999 (33pp.). cited by other . Auriacombe et al., Buprenorphine prescribed by general practitoners--A safe means of increasing patient access to treatment?, in Maintenance Treatment in Heroin Addiction--Evidence at the Crossroads (Wall and Haga, eds.), 2003 (5 pp.). cited by other . Bailey et al. Package inserts and other dosage guidelines are especially useful with new analgesic and new analgesic delivery systems. Anesth Analg. Dec. 1992;75(6):873-5. cited by other . Begaud et al., of the Joint Ministerial Mission for Combatting Drugs and Drug Addiction Information Office, Evaluation of Subutex.RTM. availability in the treatment of drug users. Summary review of the literature and available data and proposals for a research program. Jun. 1998 (83 pp.). cited by other . Brown, Jr., of American Society of American Society of Addiction Medicine, letter to DEA Administrator dated May 17, 2002 in response to notice published in the Federal Register of Mar. 21, 2002. cited by other . BTDS List of Studies (undated). cited by other . BTDS Outstanding Issues--A waiting FDA response from Oct. 2, 1999-Mar. 20, 2000. cited by other . BTDS Planned FDA Submissions/Interactions for 2000. cited by other . Buprenorphine DEA Review DocumentsScheduling under the CSA. Feb. 2002 (26 pp.). cited by other . Buprenorphine prescription withdrawn in Norway, available at http://www.drugscope.org.uk. cited by other . Buprenorphine TDS Pre-NDA Meeting, Flux rate analysis of Buprenorphine transdermal delivery systems (BTDS) (undated). cited by other . Buprenorphine transdermal system (IND 50,273) meeting minutes dated Jan. 23, 1997. cited by other . Buprenorphine transdermal system (IND 50,273) meeting minutes of Jul. 14, 1999 (8 pp.). cited by other . Buprenorphine transdermal system (IND 50,273) meeting minutes of May 16, 1996. cited by other . Buprenorphine transdermal system (IND 50,273) meeting minutes of Nov. 18, 1998. cited by other . Buprenorphine transdermal system (IND 50,273) nonclinical video conference of Feb. 24, 1997 (4 pp.). cited by other . Bushnell et al., Choosing the right analgesic. A guide to selection. Drugs. Sep. 1993;46(3):394-408. cited by other . Caplan et al., Transdermal fentanyl: An overview of clinical progress in Opioids in Anesthesia II (Estafanous, ed.), 1991(21):267-73. cited by other . Chapters 17 and 18 discussion in opioids in Anesthesia II (Estafanous, ed.)1991:223-38. cited by other . Charuvastra et al., Buprenorphine versus placebo taste test. CPDD 1994 Annual Scientific Meeting Abstract. cited by other . Clarification of pharmtox requirements for NDA (IND 50,273) meeting minutes with sponsor of Apr. 13, 1999. cited by other . Clinical chronology for BTDS NDA from May 10, 1996-Feb. 4, 2000. cited by other . CMC Chronology for BTDS NDA from Jun. 26, 1997-Mar. 2, 2000. cited by other . Cinical documentation (Part IV), vols. 6-37 Table of Contents from Grunethal GmbH as of Dec. 13, 1999. cited by other . Comparison of the analgesic efficacy and safety of buprenorphine in the form of a sublingual tablet and a transdermal therapeutic system (TTS 50) in chronic pain, Grunenthal; GmbH--Medical Department, Germany, Report No. WIS-BUP 03, May 20, 1999. cited by other . Compton et al., What dose of buprenorphine reduces opiate use? A double-blind dose-ranging study. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Controlled Substance Staff--Background material for peripheral and central nervous system advisory committee. Risk management plans for recently approved drugs. Mar. 15, 2001. cited by other . Coop et al., Ring constrained analogs of Buprenorphine. CPDD 1994 Annual Scientific Meeting Abstract. cited by other . Determination of the absolute bioavailability of buprenorphine from a transdermal therapeutic system with 2 different loadings (20 and 40 mg) in comparison to an intravenous administration in an open 3-way crossovere trial with 24 healthy male volunteers. Gruenenthal GmbH--Research Centre, Germany. Report No. FO-PK 391, May 6, 1996. cited by other . Determination of the analgesic efficacy of three buprenorphine dosages versus placebo in a transdermal therapeutic system (TTS) in patients with tumour pain and patients with chronic pain of non-tumour-related origin. Gruenenthal GmbH--Medical Department, Germany. Report No. WIS-BUP 01, Jun. 17, 1999. cited by other . Determination of the analgesic efficacy of three buprenorphine dosages versus placebo in a transdermal therapeutic system (TTS) in patients with tumour pain and patients with chronic non-tumour-related pain. Gruenenthal GmbH--Medical Department, Germany. Report No. WIS-BUP 02, Jun. 1, 1999. cited by other . Determination of the pharmacokinetic parameters of buprenorphine from a transdermal therapeutic system with 3 different loadings (20, 30, and 40 mg) in an open, balanced 3-parallel group study in 54 healthy volunteers. Chrysalis Clin. Pharmcol Services GmbH, Germany. Final Report PK 402 Integrated PK, Jun. 30, 1997. cited by other . Determination of the plasma concentration of buprenorphine from a transdermal therapeutic system with three different loadings in a patient population. Gruenenthal GmbH--Research Centre, Germany. Report No. WIS-BUP 02 PK, Jan. 20, 1999. cited by other . Follow-up treatment with buprenorphine TTS 50 after completion of the double-blind phase of studies. Gruenenthal GmbH--Medical Department, Germany. Report No. WIS-BUP FU, May 25, 1999. cited by other . Fukaze et al., Precipitation of morphine withdrawal by buprenorphine and butorphanol in male cynomolgus monkeys. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Gasfriend et al., Long-term effects of buprenorphine for treatment of combined opiate and cocaine dependence. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Guo et al., Bioadhesive buccal polymer patches for buprenorphine controlled delivery: Solubility consideration. Proceed Intern Symp Control Rel Bioact Mater. 1995. cited by other . Hawks et al., Buprenorphine-naloxone combination drug for the treatment of drug addiction. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Hayes, of FDA, Comments dated Mar. 31, 1997 regarding buprenorphine patch (IND 50,273), Mar. 31, 1997 (2 pp.). cited by other . Hogan & Hartson's supplemental filing dated Apr. 10, 2002 in support of citizen petition filed on Dec. 11, 2001. cited by other . Hogan & Hartson's response dated May 9, 2002 to 67 FR 17074 of Apr. 9, 2002. cited by other . Hogan & Hartson's comments dated May 22, 2002 to 67 FR 13114 of Mar. 21, 2002. cited by other . Human immunodeficiency virus/acquired immunodeficiency syndrome in the context of drug abuse. Report of the Executive Director, United Nations Economic and Social Council. Jan. 30, 2003 (12 pp.). cited by other . Hyman, Phelps & McNamara P.C.'s comments and objections dated Jul. 5, 2002 to the citizen petition. cited by other . Hyman, Phelps & McNamara P.C.'s comments dated May 22, 2002 on behalf of Purdue Pharma L.P. to 67 Fed. Reg. 13,114 of Mar. 21, 2002. cited by other . Hyman, Phelps & McNamara P.C.'s response dated May 9, 2002 on behalf of Purdue Pharma L.P. to 67 Fed. Reg. 17074 of Apr. 9, 2002. cited by other . Johnson et al., Daily versus alternate-day dosing of buprenorphine in the outpatient treatment of opioid dependence. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Jones et al., Buprenorphine and naloxone interactions in heroin-dependent volunteers. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Journal of Pain and Symptom Management. Apr. 7, 1992 (S3) (whole journal). cited by other . Kintz, Deaths involving buprenorphine: A compendium of French cases. Forensic Sci Int. Sep. 15, 2001;121(1-2):65-9. cited by other . Korte, Titration with TTS fentanyl systems for previously uncontrolled cancer pain, and Lipman's response thereto. Anesth Analg. Sep. 1994;79(3):612-4. cited by other . Kumar, Chemists selling illegal drugs to be booked in The times of India, Aug. 16, 2000. cited by other . Lasseter et al., Systemic pharmacokinetic (PK) study of buprenorphine (B) in mild to moderate chronic hepatic impairment (CHI). Amer Soc for Clin Phamcol and Therapeut. PI-4. cited by other . Liguori et al., Modification of respiratory effects of levorphanol by nalbuphine, butorphanol, and buprenorphine in rhesus monkeys. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Mann et al., Buprenorphine alone or in combination with naltrexone for inpatient medically supervised opiate withdrawal. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . McCance-Katz, of American Academy of Addiction Psychiatry, letter to DEA Administration dated May 15, 2002 in response to proposed rule : Rescheduling of Buprenorphine from Schedule V to Schedule III, published in the Federal Register of Mar. 21, 2002. cited by other . McNeal, of FDA, Medical Review on IND 40,273, dated May 10, 1996. cited by other . McNeal, of FDA, Comments dated Aug. 30, 1996 on the protocols submitted on Aug. 5, 1996 in Serial No. #006 of IND 50,273. cited by other . McNicholas et al., Buprenorphine clinical practice guidelines. Field review draft. Nov. 17, 2000. cited by other . Mendelson et al., Buprenorphine treatment improves brain perfusion abnormalities in men with concurrent cocaine and heroin dependence: A spect brain imaging analysis. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Miller, Memorandum to Brogden, Napp Pharmaceuticals Ltd., re Evaluation of clinical data received from Grunenthal buprenorphine TTS, Nov. 11, 1999 (5 pp.). cited by other . Non-Clinical Chronology for BTDS NDA from May 1996-Apr. 2000. cited by other . O'Connor et al., A pilot study of primary care-based buprenorphine maintenance. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . O'Keeffe, of Reckitt Benckiser Pharmaceuticals Inc. letter to DEA Administrator dated Apr. 18, 2002 in response to proposed rule : Rescheduling of buprenorphine from Schedule V to Schedule III, published in the Federal Register on Mar. 21, 2002. cited by other . Payne et al., The role of transdermal fentanyl in the management of cancer pain in Opioids in Anesthesia II (Estafanous, ed.), 1991(18):215-22. cited by other . Pharmaceuticals: Restrictions in Use and Availability, Mar. 2001 (up to p. 5 re Buprenorphine). cited by other . Pilot study on the dermal tolerability and adhesion of a buprenorphine patch and the absorption of the active substance over an application period of 72 hours in 6 healthy volunteers, Final Report, 1992. cited by other . Portenoy et al. Acute and chronic pain in Substance Abuse. A Comprehensive Textbook (Lowinson et al., eds.), 2.sup.nd ed. 2005. 52:691-721. cited by other . Preston et al., Abuse liability evaluation of buprenorphine in buprenorphine-treated patients. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Report of the International Narcotics Control Board for 2001, United Nations Publication. cited by other . Rigas et al., Transdermal fentanyl: Practical use in the hospital and the home (undated). cited by other . Schuh, A comparison of buprenorphine's and naltrexone's opioid blockade abilities. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Segal et al., A double blind, multicenter clinical trial comparing four doses of buprenorphine. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Singh et al., Cases of buprenorphine abuse in India. Acta Psychiatr Scand. Jul. 1992;86(1):46-8. cited by other . Smith, Grunenthal buprenorphine trandermal system. Review of pharmacokinetic studies. 11/10/199 (7 pp.). cited by other . Steiberg et al., Acute toxic delirium in a patient using transdermal fentanyl. Anesth Analg. Dec. 1992;75(6):1014-6. cited by other . The Safety of High Doses of Buprenorphine. Table of Contents and Introduction (undated). cited by other . Using buprenorphine for office-based treatment of opiate addiction. Recommendations to the CSAT of the SAMHSA, from CSAT's National Advisory Council, approved by the CSAT's National Advisory Council on Sep. 15, 1999 (28 pp.). cited by other . Wang et al., Negative opiates in urine of patients on buprenorphine study. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . WHO Critical review of psychoactive substances. 33.sup.rd Expert Committee on Drug Dependence, Sep. 17-20, 2002. cited by other . WHO Expert Committee on Drug Dependence 25.sup.th Report. WHO Technical Report Series. 1989. cited by other . WHO Expert Committee on Drug Dependence 32.sup.nd Report. WHO Technical Report Series. 2001. cited by other . WHO Expert Committee on Drug Dependence 33.sup.rd Report. WHO Technical Report Series. 2003. cited by other . Wodak, Additional commentary on a proposed review of the classification of buprenorphine in Schedule III of the 1971 Convention on Psychotropic substances (undated). cited by other . Ziedonis et al., Depression in cocaine abusing opioid addicts treated with buprenorphine versus methadone. CPDD 1994 Annual Scientific Meeting Abstracts. cited by other . Bell et al., Evaluation of transdermal fentanyl for multi-day analgesia in postoperative patients. Anesth Analg. 1989; Abstract S22. cited by other . Fiset et al., Biopharmaceutics of a new transdermal fentanyl device. Anesthesiology. Sep. 1995;83(3):459-69. cited by other . Gibaldi, Prolonged-Release medication in Biopharmaceutics and Clinical Pharmacokinetics. 1984;3.sup.rd ed.:113-30. cited by other . Hadgraft, In vitro testing of dermal and transdermal products. Mar. 28, 2001 (6 pages). cited by other . Harvey-Clark et al., Transdermal fentanyl compared with parenteral buprenorphine in post-surgical pain in swine: a case study. Lab Anim. Oct. 2000;34(4):386-98. cited by other . Imoto et al., Transdermal prodrug concepts: permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles. Biol Pharm Bull. Feb. 1996;19(2):263-7. cited by other . Michaels et al., Drug permeation through human skin: Theory and in vitro experimental measurement. AIChE J. 1975;21(5):985-96. cited by other . New Approaches to Pain Management. Progress in Palliative Care. Meeting Report. Oct. 12-13, 2000; 100-101. cited by other . Portenoy et al., Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology. Jan. 1993;78(1):36-43. cited by other . Stinchcomb et al., Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. Pharm Res. Oct. 1996;13(10):1519-23. cited by other . Hihuchi, William I., Ph.D. et al., "Particle Phenomena and Coarse Dispersions" Chapter 21, p. 194. cited by other . Colloidal Dispersions, p. 267. cited by other . Climara.RTM. Product Information, Physicians' Desk Reference (1998) pp. 672-676. cited by other . Catapres TTS.RTM. Product Information, Physicians' Desk Reference (1998) pp. 610-612. cited by other . Chien, pp. 31-44, col. 8 and 9. cited by other . McQuinn, R.I., et al., "Sustained oral mucosal delivery in human volunteers of buprenorphine from a thin non-eroding mucoadhesive polymeric disk" J. Contr. Rel. (1995). cited by other . Van Buskirk, G.A. et al., "Scale-up of adhesive transdermal drug delivery systems" Pharmaceutical Research 14(7) (1997). cited by other . Sadee, W. et al., "Buprenorphine: Differential interaction with opiate receptor subtypes in vivo" J. Pharm. Exp. Ther. 223(1) 1982. cited by other . Kuhlman, J.J., et al., "Human pharmacokinetics of Intravenous, sublingual and buccal buprenorphine" J. Anal. Toxicol. v 20 (1996). cited by other . Roy, S.D. et al., Transdermal delivery of buprenorphine through cadaver skin J. Pharm. Sci. 83(2): 126-30 (1994). cited by other . Wilding, I.R. et al., "Pharmacokinetic evaluation of transdermal buprenorphine in man" Int.I J. Pharmaceutics 132:81-7 (1996). cited by other . Roy et al., "Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design," J Pharm Sci. May 1996, 85(5):491-5. cited by other . Friend et al., Simple alkyl esters as skin permeation enhancers. J. Controlled Release 1988 9:33-41. cited by other . Friend et al., Transdermal delivery of levonorgestrel I: Alkanols as permeation enhancers in vitro, J. Controlled Release 1988 7:243-50. cited by other . Agin M, Kazierad DJ, Abel R, et al., Assessing QT variability in healthy volunteers. J. Clin. Phamacol. 2003; 43:1028. cited by other . Ahmadi, J. et al., Treatment of heroin dependence. German Journal of Psychiatry 2004;7(2): 1-5. cited by other . Baker JR. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Annals of Pharmacotherapy 2006; 40:392-6. cited by other . Bauer, K.H. et al. Pharmazuetische Technologie, (1986) pp. 362-365. cited by other . Bigelow GE. Forward. In: Cowan A, Lewis JW, eds. Buprenorphine: Combating Drug Abuse With a Unique Opioid. New York, NY: Wiley-Liss: 1995:xi-xiii. cited by other . Bliesener N, et al., Plasma Testosterone and Sexual Function in Men Receiving Buprenorphine Maintenance for Opioid Dependence. The Journal of Clinical Endocrinology & Metabolism 90(1):203-6, 2005. cited by other . Boger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliative medicine 2006; 20:S17-S23. cited by other . Briefing document, cardiovascular and renal drug products advisory committee. May 29, 2003. Division of reproductive and arologic drug products. Apr. 29, 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3956B1_01_FDA-alfuzosin.p- df. cited by other . Bruce RD. Pharmacokinetic interactions between buprenorphine and antiretroviral mediations. Clinical Infectious Diseases 2006; 43 (Suppl 4):S216-S223. cited by other . Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo Pj, Popp B, Portenoy RK, Foley KM, Opioid Pharmacotherapy in the Management of Cancer Pain: A Survey of Strategies Used by Pain Physicians for the Selection of Analgesic Drugs and Routes of Administration. Cancer 1995; 76:1288-1293. cited by other . Ciraulo DA. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. Journal of Clinical Pharmacology 2006;46(2):179-92. cited by other . Cranmer, K. W. et al., Transdermal buprenorphine (BTDS) on associated health outcomes in th elderly. Presented at the 11th World Congress on Pain, Sydney, Australia, Aug. 21-26, 2005; Abstr 691-P297. (Study sponsored by Purdue Pharma L.P.). cited by other . Cymbalta.RTM. ((duloxetine hydrochloride) Delayed-release Capsules) Package Insert. cited by other . Dahan A. Opioid effects on respiratory function and analgesia: New data on buprenorphine and fentanyl in a new human model [abstract]. 3.sup.rd Research Forum of the European Association for Palliative Care, Stresa, Italy, 2004. cited by other . Duragesic.RTM. [package insert]. Titusville, NJL Janssen Pharmaceutica; 2001. cited by other . Eissenberg T et al., Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans. J. Pharmacol. Exp. Ther. 276: 449-459, 1996. cited by other . Escher, M. et al., Pharmacokinetics and analgesic effects of intravenous buprenorphine (abstract). Clinical Pharmacology and Therapeutics 2005; 77(2 Suppl): 51. cited by other . Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons; 1981:33-45, 272-273 (Table A.3). cited by other . Flitz J. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. European Journal of Pain 2006;10(8):743-8. cited by other . Gaulier J-M, et al., Ingestion of High-Dose Buprenorphine by a 4 Year-Old Child. Journal of Toxicology-Clinical Toxicology 42(7):993-5, 2004. cited by other . Gerra G. Naltrexone and buprenorphine combination in the treatment of opioid dependence. Journal of psychopharmacology 2006;20(6):806-14. cited by other . Hale ME, Ahdieh H, Ma T, Rauck R, for the Oxymorphone ER Study Group. Efficacy and Safety of OPANA ER (Oxymorphone Extended Release) for Relief of Moderate to Severe Chronic Low Back Pain in Opioid-Experienced Patients: A 12-Week, Randomized, Doubleblind, Placebo-controlled Study. J Pain 2007; 8(2):175-184. cited by other . Halpern SD, Karlawish JHT, Berlin JA. The Continuing Unethical Conduct of Underpowered Clinical Trials. JAMA 2002; 288:358-362. cited by other . Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1979; 17:81-110. cited by other . Heilman, K. Therapeutische Systeme (1984) pp. 26-27 and pp. 48-53. cited by other . Herve S, et al., Acute hepatitis due to buprenorphine administration. European Journal of Gastroenterology & Hepatology 16(10):1033-7, 2004. cited by other . Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs. 1991; 41(3):326-344. cited by other . ICH harmonized tripartite guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, E14, Final Draft May 12, 2005. Available at [http://www.ich.org/cache/compo/475-272-1.html#E14]. cited by other . Jagadheesan K and Muihead D., Possible manic potential of buprenorphine [letter]. Australian and New Zealand Journal of Psychiatry 37*8):560-1, 2004. cited by other . Katchman AN, McGroary KA, Kilborn MJ, et al., Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents, 2002. J Pharmacol Exp Ther 303:688-94. cited by other . Kolloch RE, Mehlburger L, Schumacher H, Gobel BO. Efficacy and safety of two different galenic formulations of a transdermal clonidine system in the treatment of hypertension. Clin Auton Res. 1993;3:373-378. cited by other . Kosten T, et al., Depression Predicts Higher Rates of Heroin Use on Desipramine with Buprenorphine than with Methadone. The American Journal of Addictions 13:191-201, 2004. cited by other . Krantz, M.J. et al., Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy 2005; 25(4):611-614. cited by other . Landau, C.J. et al., The safety and tolerability of buprenorphine 7-day transdermal system in patients with nonmalignant pain syndromes responsive to opioids. Presented at the 11th World Congress on Pain, Sydney Australia, Aug. 21-26, 2005; Abstr. 690-P296 (Study sponsored by Purdue Pharma L.P.) cited by other . McCance-Katz EF. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clinical infectious Diseases 2006; 43 (Suppl 4):S235-S246. cited by other . McCance-Katz EF. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reserve-transcriptase inhibitors efavirenz and delavirdine. Clinical infectious Diseases 2006; 43 (Suppl 4):S224-S234. cited by other . McMahon FG, Jain AK, Vargas R, Fillingim J. A double-blind comparison of transdermal clonidine and oral captopril is essential hypertension. Clin. Ther. 1990; 12:88-100. cited by other . Muriel, C. et al., Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-lable, uncontrolled, prospective, observational clinical study. Clinical Therapeutics 2005; 27(4):451-462. (Study sponsored by Grunenthal GmbH). cited by other . Neri, S. et al., Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology 2005; 179(3): 700-704. cited by other . Nielsen, S.; Taylor, D.A. The effect of buprenorphine and benzodiazepine on respiration in the rat. Drug and Alcohol Dependence 2005;79:95-101. cited by other . Noveck, R. et al., Lack of effect of inhibitor ketoconazole on transdermally administered buprenorphine. Presented at the 106th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, FL., Mar. 2-5, 2005. (Study sponsored by Purdue Pharma L.P.). cited by other . Opana.RTM. ER ((Oxymorphone Hydrochloride) Extended Release Tablets)) Package Insert. cited by other . Patterson S, Agin M, Anziano R, et al., Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations. Report from the pharmaceutical research and manufacturers of American QT statistics expert team. Drug Information Journal 2003:39:243-265. cited by other . Philipz, J. et al., Pharmacokinetics of transdermal buprenorphine (Transtec.RTM.) in patients with renal insufficiency. Presented at the 9th Congress of the European Association for Palliative Care, Aachen, Germany, Apr. 8-10, 2005. (Study sponsored by Grunenthal GmbH). cited by other . Pimay S, et al., A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 99: 978-88, 2004. cited by other . Quang-Cantagrel N.D., Wallace M.S., Magnuson S.K. Opioid Sunstitution to Improve the Effectiveness of Chronic Noncancer Pain Control: A Chart Review. Anest Anag 2000; 90:933-937. cited by other . Raja SN, Haythornthwaite, JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, Royall RM, and Max MB. Opioids versus antidepressants in postherpetic neuralgia: A randomized, placcebo-controlled trial. Neurology. 59: 1015-1021, 2002. cited by other . Rozenbaum H, Birkhauser M, DeNooyer C, et al., Comparison of two estradiol transdermal systems (Oesclim.RTM. 50 and Estraderm TTS.RTM. 50). II. Local skin tolerability. Maturitas. 1996; 25:175-185. cited by other . Schmid-Grendelmeier P. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Current Medical Research and Opinion 2006;22(3):501-9. cited by other . Sittl, R. et al., Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: Results of a retrospective cohort study. Clinical Therapeutics 2005; 27(2):225-237. (Study sponsored by Grunenthal GmbH). cited by other . Soyka, M. et al., Less impairment on one of portion of a driving-relevant psychomotor battery in buprenorphine-maintained that in methadone-maintained patients: results of a randomized clinical trial. Journal of Clinical Psychopharmacology 2005; 25(5): 490-493. cited by other . Sporer KA, Buprenorphine: A Primer for Emergency Physicians. Annals of Emergency Medicine 43(5):580-4, 2004. cited by other . Turk DC, Melzack R. The measurement of pain and the assessment of people experiencing pain. In: Turk DC, Melzack R, eds. Handbook of Pain Assessment. New York, NY: The Guilford Press; 1992:3-12. cited by other . World Medical Association Declaration of Helsinki. Ethical Principals for Medical Research Involving Human Subjects. 2004. cited by other . Yassen A. Mechanisms-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clinical Pharmacology & Therapeutics 2007:81(1):50-8. cited by other . Wallenstein, "Crossover Trials in Clinical Analgesic Assays: Studies of Buprenorphine and Morphine" Pharmacotherapy 6(5):228-235 (1986). cited by other . Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. JPain Symptom Manage 2005:29:297-326. cited by other . Lemens HJM, Wada DR, Munera C, El-Tahtawy A, Stanski DR. Enriched analgesic efficacy studies: an assessment by clinical trial simulation. Contemp Clin Trials, 2006:27; 165-173. cited by other . Cranmer K, Landau CJ, Friedman My Turner NG, Ripa SR. The safety and tolerability 0 of 7-day buprenorphine.TDS in the analgesic management of pain in the elderly--a 6-month evaluation. www.ASCP.com/education/postersandpapersam05.com. Poster 34. (Study BUP 3002S). cited by other . D'Ambrosio P, McCarberg By Landau CJ, Hsu Y, Colucci R, Ripa S. Conversion from Vicodin.RTM. to buprenorphine transdermal system in subjects with osteoarthritis pain. J Pain 2006; 7(4) (Suppl 2): S5 1. Abstract 801. (Study BUP3018). cited by other . Harris S, Hoelscher D, Kristensen A, O'Keefe S, Schemera A. Effects of buprenorphine transdermal system 10 mg and 2.times.20 mg on QT intervals in healthy subjects. Clin Pharmacol ner 2006; 79(2):P35. (Study BUP1011). cited by other . Razzetti AJ, Carr W, Landau CJ, Munera C, Ripa SR, Sessler N. Effectiveness of 7-day buprenorphine transdermal system in the management of chronic nonmalignant pain syndromes. J Pain 2005; 6(3): Suppl 1:542. (Study BUP 3201). cited by other . Schnoll SH, Smith MY, Colucci RD, Munoz A. Development of a denominator for calculating rates of opioid abuse. CPDD Annual Meeting Abstractcs. 2004. (Study BUP3018 and non BTDS studies). cited by other . Shannon MJ, Kivitz A, Landau CJ, Sessler NE, Xia Y, Ripa SR. Buprenorphine transdermal system in chronic pain due to osteoarthitis. Arch Phys Med Rehabil 2005; 86(9):e32. (Study BUP3012). cited by other . Spyker DA, Hale ME, Lederman My Creanga DL, Coles C, Reder RF, Long-term use of buprenorphine transdermal system (BTDS) in patients with chronic pain. JAm Geriatr Soc 2002; 50(4 suppl):S66. Abstract P162. (Study BP96-0103). cited by other . Spyker DA, Hale ME, Munera CL, Wright C. Treatment of patients with chronic low back pain with buprenorphine transdermal system (BTDS) compared with hydrocodone/acetaminophen. Pain Mgmt 2001 :PF2001-85. (Study BP98-1201z). cited by other . Wright C, Zalman M-A, Haddox JD, Kramer ED, Colucci RD, D'Ambrosio P., Systematic assessment of abuse or diversion in a clinical trail of analgesics. CPDD Annual Meeting Abstracts. 2006. (Study BUP3018). cited by other . Barry, "Reflections on Transdermal Drug Delivery", Pharmaceutical Science & Technology Today 2(2):41-43 (1999). cited by other . Catapres TTS.RTM. Product Information, Physicians' Desk Reference 1998, pp. 610-612. cited by other . Climara.RTM. Product Information, Physicians' Desk Reference 1998, pp. 672-6. cited by other . Kuhlman, Jr., et al., Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. Oct. 1996;20(6):369-78. cited by other . McQuinn, R.L. et al., Sustained oral mucosal delivery in human volunteers of buprenorphine from a thin non-eroding mucoadhesive polymeric disk. Journal of Controlled Release 1995, 34:243-50. cited by other . Roy et al., Transdermal delivery of buprenorphine through cadaver skin. J Pharma Sci 1994, 83(2):126-30. cited by other . Sadee et al., Buprenorphine: Differential interaction with opiate receptor subtypes in vivo. The Journal of Pharmacology and Experimental Therapeutics, Copyright .COPYRGT. 1982, 223(1):157-62. cited by other . Van Buskirk et al, Scale-up of adhesive transdermal drug delivery systems. Pharmaceutical Research 1997, 14(7). cited by other . Wilding et al., Pharmacokinetic evaluation of transdermal buprenorphine in man. International Journal of Pharmaceutics 1996, 132:81-7. cited by other . Ashcroft et al., Buprenorphine TDS: Comparison with sublingual buprenorphine in osteoarthritic pain. 10.sup.th World Congress on Pain, Aug. 19, 2002 Abstract 510-P144. cited by other . Becker et al., Transdermal buprenorphine: Abuse potential assessment in non-opioid-dependent volunteers. CPDD Jun. 16-21, 2001 Abstract 40 (w/ PowerPoint presentation). cited by other . Boas et al., Clinical actions of fentanyl and buprenorphine the significance of receptor binding. Br. J. Anaesth. 1985, 57:192-6. cited by other . Buprenorphine Product Photo, Norspan.TM. 5, 10 & 20. cited by other . Capurso et al., Matrix transdermal technology: focus on a buprenorphine transdermal system. ASHP Midyear Clinical Meeting, Dec. 2001, p. 231D Abstract (w/ PowerPoint presentation). cited by other . Colucci, History of Buprenorphine. PowerPoint presentation presented in Dec. 2002. cited by other . El-Tahtawy et al., 7-Day bioavailability of buprenorphine from a novel transdermal system in demographic subgroups. 13.sup.th Annual ACCP Meeting Abstracts, Sep. 23-25, 2001, p. 1027, Abstract 56 (w/ PowerPoint presentation). cited by other . Friend et al., Simple alkyl esters as skin permeation enhancers. J. Controlled Release 1988 9:33-41. cited by other . Friend et al., Transdermal delivery of levonorgestrel I: Alkanols as permeation enhancers in vitro, Controlled Release 1988 7:243-50. cited by other . Hale et al., Analgesic efficacy of buprenorphine transdermal systems vs. Oxy/APAP in patients with chronic low back pain. The Gerontologist, vol. 41, Special Issue 1, Oct. 2001, Program Abstracts from the Gerontological Society of America 54.sup.th Annual Scientific Meeting, Nov. 15-18, 2001, p. 25 (w/ PowerPoint presentation first presented on May 7, 2002 and revised on Oct. 30, 2002). cited by other . Hale et al., Dose proportionality and the dose response of buprenorphine transdermal system in patients with chronic pain. 13.sup.th Annual ACCP Meeting Abstracts, Sep. 23-25, 2001, p. 1027, Abstract 58 (w/ PowerPoint presentation). cited by other . Hale et al., Long-term use of buprenorphine transdermal system (BTDS) in patients with chronic pain. PowerPoint presentation presented May 2002. cited by other . Hale et al., Treatment of patients with chronic low back pain with buprenorphine transdermal systems (BTDS) compared with hydrocodone/acetaminophen. National Clinical Symposium of the American College of Nurse Practitioners, Oct. 20, 2001 Abstract (w/ PowerPoint presentation). cited by other . Jaffe et al., Opioid Analgesics and Antagonists. The Pharmacological Basis of Therapeutics (8.sup.th ed. Pergamon Press) 1990, Chap. 21, pp. 485-521. cited by other . Jeal et al., Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs, Jan. 1997, 53(1):109-38. Review. cited by other . Kaiko et al., Transdermal buprenorphine. Memorial Sloan Kettering Manuscript, Chapter 15 (w/ PowerPoint Final presentation presented May 2, 2003). cited by other . Lasseter et al., Systemic pharmacokinetic (PK) Study of buprenorphine (B) in mild to moderate chronic hepatic impairment (CHI). Amer. Society for Clinical Pharmacology and Therapeutics 69(2) 2 (P1-4) Feb. 2001 Abstract (w/ PowerPoint presentation presented Mar. 2001). cited by other . Marquardt et al., Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother Oct. 1995, 29(10):969-71. cited by other . Muller et al., Intra--and postoperative interactions between the 2 opioids fentanyl and buprenorphine. Anaesthesist. Apr. 1986, 35(4):219-25 (in German, w/ English abstract). cited by other . Noveck et al., Pharmacokinetics of buprenorphine transdermal system (BTDS 10) employing the LPS pyrogen model. Clinical Pharmacology & Therapeutics 69(2):3 200 2001 Abstract PI-7 (w/ PowerPoint presentation). cited by other . Payne et al., Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs. Apr. 1995, 6 Suppl 3:50-3. cited by other . Peng et al., A review of the use of fentanyl analgesia in the management of acute pain in adults. Anaesthesiology 1999, 90:576-99. cited by other . Reidenberg et al., Absolute bioavailability of a novel buprenorphine transdermal system (BTDS) applied for 7 days. J. Clin Pharmacol. 2001 41(9):1014-1033, Abstract 55, p. 1026 (w/ PowerPoint presentation presented in the ACCP Meeting, Sep. 2001). cited by other . Reidenberg et al., Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to 7 days. J. Clin Pharmacol. 2001 41(9):1014-1033, Abstract 57, p. 1027 (w/ PowerPoint presentation). cited by other . Reidenberg et al., Pharmacokinetics and safety of buprenorphine transdermal system (BTDS) for 7-Day application comparing healthy elderly and young adult subjects. Am Pain Soc, 19.sup.th Ann. Sci. Meet., Nov. 2-5, 2000 Abstract 776 (w/ PowerPoint presentation). cited by other . Reidenberg et al., Physiologic effects of buprenorphine transdermal system (BTDS) dose escalation in the young, healthy elderly and elderly hypertensive subjects, FASEB J. 15(4), Mar. 2001 Abstract 457.3 (w/ PowerPoint presentation presented Apr. 2001). cited by other . Roy et al., "Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design," J Pharm Sci. May 1996, 85(5):491-5. cited by other . Sandler et al., A Double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesis, respiratory, and pharmacokinetic effects, Anesthesiology Nov. 1994, 81(5):1169-80; discussion 26A. cited by other . Spyker et al., Effectiveness and safety of buprenorphine transdermal system (BTDS) compared with hydrocodone/acetaminophen in the treatment of patients with chronic low back pain. J. Pain 2002 3(Suppl. 1):14 Abstract 653 (w/ PowerPoint presentation). cited by other . Spyker et al., Effectiveness of buprenorphine transdermal system (BTDS) compared with oxycodone/acetaminophen and placebo in the treatment of patients with chronic back pain. Morial Convention Center, Oct. 15, 2001 Abstract (w/ PowerPoint presentation). cited by other . Spyker et al., Transdermal buprenorphine system (BTDS) in patient-controlled Analgesia (PCA). PowerPoint presentation presented Mar. 2000. cited by other . Spyker et al., Analgesic efficacy and safety of buprenorphine transdermal system (BTDS) in patients with osteoarthritis. The Journal of Pain 3(2, Suppl. 1):12 Abstract 645(w/ PowerPoint presentation). cited by other . Spyker et al., Effect Size (ES) Meta-analysis Approach to Noninferiority Clinical Trials. Clinical Pharmacology & Therapeutics 69(2):33 Abstract PII-3 (w/ PowerPoint presentation presented Mar. 5, 2001). 0. cited by other . Transtec Summary of Product Characteristics, Oct. 2003. cited by other. |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.